1 Foreword

2 Summary of recommendations

3 Contents: Published questions

Note that these questions are not open for review and public consultation.

What are the clinical features of melanoma and how do atypical melanomas present?

What type of biopsy should be performed for a suspicious pigmented skin lesion?

When is a sentinel node biopsy indicated?

What are the recommended definitive margins for excision of primary melanoma?

- Excision margins for melanoma in situ
- Excision margins for invasive melanomas and melanomas at other sites

Please see here to access the Clinical Practice Guidelines for the Management of Melanoma in Australia and New Zealand (2008). Note this resource was developed, reviewed or revised more than five years ago. It no longer represents the National Health and Medical Research Council's position on the matters contained therein. An updated version of this guideline is in progress. This PDF has been made available for reference purposes only.
Diagnostic aids for melanoma

- What is the role of dermoscopy in melanoma diagnosis?
- What is the role of sequential digital dermoscopy imaging in melanoma diagnosis?
- What is the role of automated instruments in melanoma diagnosis?
- What is the role of confocal microscopy in melanoma diagnosis?

What is the appropriate treatment for macroscopic (i.e. detectable clinically or by ultrasound) nodal metastasis?

4 Appendices

Guideline development process
Working party members and contributors
List of clinical questions (including other questions under development)
Conflict of interest register

1 Foreword

1.1 Foreword

Australia and New Zealand have the highest incidence of melanoma in the world, and comprehensive, up-to-date, evidence-based national guidelines for its management are therefore of great importance. Both countries have populations of predominantly Celtic origin, and in the course of day-to-day and recreational activities their citizens are inevitably subjected to high levels of solar UV exposure. These two factors are considered to be predominantly responsible for the very high incidence of melanoma (and other forms of skin cancer) in the two nations. In Australia melanoma is the third most common cancer in men and the fourth most common in women, with over 13,000 new cases and over 1,750 deaths each year. [1]

The purpose of evidence-based clinical guidelines for the management of any medical condition is to achieve early diagnosis whenever possible, make doctors and patients aware of the most effective treatment options, and minimise the financial burden on the health system by documenting investigations and therapies that are inappropriate. The first Australian guidelines for the management of melanoma were published in 1999 under the auspices of the Australian Cancer Network, whose CEO Professor Tom Reeve AC CBE encouraged and supported their development and promulgation. A multidisciplinary working party convened by Professor William McCarthy AM rigorously assessed all available evidence, and on this basis the guidelines received
Clinical practice guidelines for the diagnosis and management of melanoma

endorsement from the Australian National Health and Medical Research Council (NHMRC). Within a few years it was clear that updating of the guidelines was required, and another working party was assembled, with myself as chairman, to produce new evidence-based guidelines. On this occasion, New Zealand representatives were included in the working party, and the resulting guidelines published in 2008 were endorsed not only by the NHMRC in Australia but also by the New Zealand Melanoma Guidelines Group. NHMRC endorsement was achieved once again because that body was satisfied that its required process for the development of evidence-based guidelines had been followed.

In 2014, with many further advances in melanoma diagnosis and management having been made, it was apparent that yet another revision of the Australian melanoma management guidelines was necessary. However, there was concern that the process used to develop the two previous sets of national guidelines would be too protracted and cumbersome in an era when rapid advances in management are occurring. Nor was any funding readily available to proceed along the same lines as previously, i.e. following the strict NHMRC requirements for the production of guidelines. A possible solution to the problem was proposed by Professor Ian Olver AM, then CEO of Cancer Council Australia. He suggested that using an electronic “wiki” platform, guidelines could be produced in a way that allowed individual sections to be updated as new evidence became available. This method had already been used successfully by Cancer Council Australia to produce national clinical practice guidelines for the management of lung cancer, sarcoma, and Barrett’s oesophagus.

The web-based wiki platform supports all processes of guidelines development, such as the literature search, critical appraisal, data extraction, evidence assessment and summary processes, as well as content and recommendation development, online consultation, review and web publication. It is in line with the NHMRC guidelines requirements, designated standards of quality, process and grading system for recommendations. An infrastructure is set in place to process literature updates and continuously update content as new evidence emerges and is reviewed. The Development of Clinical Practice Guidelines using Cancer Council Australia’s Cancer Guidelines Wiki Handbook illustrates the steps in the development of Cancer Council Australia’s web-based clinical practice guidelines. It provides information to assist working party members and staff members to develop concise clinical questions in “PICO” format (P=Population, I=Intervention, C=Comparison, O=Outcomes), construct sound search strategies, systematically search the literature, critically appraise, summarise the evidence and formulate guidelines recommendations.

To develop the new management guidelines, Melanoma Institute Australia agreed to work in partnership with CCA using its wiki platform, with both organisations contributing to funding and providing in-kind resources. I took on the role of chairman, and a small management committee was appointed to oversee the guidelines revision process. Subsequently, a full multidisciplinary working party of individuals from all relevant disciplines was recruited, together with consumer representatives and members of the Cancer Council Australia Clinical Guidelines Network, headed by Ms Jutta von Dincklage (see full membership). The Skin Cancer College Australasia later joined the project and provided additional funding to enable employment of an additional full-time project officer in the systematic review team.

In November 2014, at an initial meeting of the guidelines working party, 23 questions were identified as being of greatest importance, covering issues relating to diagnosis, staging and management of cutaneous melanoma. These questions were then prioritised and work commenced immediately, with relevant evidence collected for each question then critically appraised by the systematic review team. Each publication bearing on the question
was structured according to the “PICO” format for the systematic review.[6] Small expert sub-committees, each headed by a lead author, were then given the task of formulating guidelines for the each clinical question and documenting the level of evidence supporting each recommendation. For matters outside the scope of the systematic review and when there was no good evidence available “practice points” were developed for inclusion in the guidelines (as in the two previously published Australian guidelines). Full details of the guidelines development process are given elsewhere.

An important contribution to the process of formal critical evaluation of available evidence, for which we are most grateful, was made by Professor Claus Garbe, Chairman of the German Dermatologic Cooperative Oncology Group (DeCOG) Committee on Guideline Development, who offered to let us use the systematic reviews that had recently been undertaken to produce updated German guidelines for melanoma management. These German guidelines had been published in 2013, so where the same questions were being considered, this greatly reduced the workload for the Australian systematic review team because they were able to limit update the systematic reviews with the publications that had appeared since 2012. In return, it was agreed that new data extractions and critical appraisals would be shared with the German group.

Made possible by use of the wiki platform, each chapter of the new Australian melanoma management guidelines will be published online when it is completed. After a draft has been prepared by each chapter group, it is released for public consultation, then finalised and approved for publication by the entire working group. At the time of preparing this Foreword the first four chapters have completed this process and are being published. They are:

- Type of biopsy
- Clinical features and atypical melanoma
- When is a sentinel node biopsy indicated?
- Recommended definitive margins for excision of primary melanoma

Subsequent chapters dealing with other important clinical questions will be published later, as they are completed and ratified by the working party, and chapters already published will be revised as relevant new evidence to guide management becomes available. These guidelines will thus be a living document, rather than a static printed publication that would inevitably be out of date within a very short time. It is hoped that wide dissemination of these guidelines and adherence to their recommendations will benefit melanoma patients in Australia by ensuring that they receive the most appropriate care.

Professor John Thompson AO

Chair, Melanoma Guidelines Working Party

1.1.1 Acknowledgments

The preparation of clinical guidelines of this nature involves a great deal of hard work by many people, and as chairman of the working party I acknowledge the contributions of all members of the group, particularly the chapter leaders. I also acknowledge those who undertook the arduous task of critical literature selection and appraisal, and the staff of the Clinical Guidelines Network of Cancer Council Australia, particularly its head Ms Jutta von Dincklage, who drove the project forward with great zeal and efficiency.
1.2 References


2 Summary of recommendations

This page provides a summary of the recommendations of the completed Melanoma guidelines contents. Other sections of the guidelines are currently in progress and will be published iteratively.

For explanation of the different types of recommendations, see below.

You may also like to refer to the Guideline development process for details on the levels of evidence and recommendation grades.
2.1 Recommendations

2.1.1 What are the clinical features of melanoma and how do atypical melanomas present?

**Practice point**

Melanomas are generally distinguished from benign lesions by their history of change and thick melanomas often do not conform to the ‘ABCD’ rule, but are Elevated, Firm and Growing. Therefore, careful history taking is important and any lesion that continues to grow or change in size, shape, colour or elevation over a period of more than one month should be biopsied and assessed histologically or referred for expert opinion.

**Practice point**

Suspicious raised lesions should be excised and not monitored.

Back to top

2.1.2 What type of biopsy should be performed for a pigmented lesion suspicious for melanoma?

**Evidence-based recommendation**

The optimal biopsy approach for a suspicious pigmented lesion is complete excision with a 2 mm clinical margin and upper subcutis.

**Evidence-based recommendation**

Partial biopsies may not be fully representative of the lesion and need to be interpreted with caution and in light of the clinical findings to minimise incorrect false negative diagnoses and understaging.

**Evidence-based recommendation**

In carefully selected clinical circumstances (such as large in situ lesions, large facial or...
### Evidence-based recommendation

When is sentinel lymph node biopsy (SLNB) indicated?

<table>
<thead>
<tr>
<th>Evidence-based recommendation</th>
<th>Grade</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sentinel lymph node biopsy should be considered for all patients with melanoma greater than 1 mm in thickness and for patients with melanoma greater than 0.75 mm with other high risk pathological features to provide optimal staging and prognostic information and to maximise management options for patients who are node positive.</td>
<td>B</td>
</tr>
</tbody>
</table>

**Practice point**

Sentinel lymph node biopsy (SLNB) should be performed at the time of the primary wide excision.
Clinical practice guidelines for the diagnosis and management of melanoma

Practice point

Sentinel lymph node biopsy (SLNB) should be performed in a centre with expertise in the procedure, including nuclear medicine, surgery and pathology to optimise the accuracy of the test.

Practice point

Patients being considered for sentinel lymph node biopsy (SLNB) should be given an opportunity to fully discuss the risks and benefits with a clinician who performs this procedure.

Practice point

A consideration of sentinel lymph node biopsy (SLNB) forms an important part of the multidisciplinary management of patients with clinically node negative cutaneous melanoma.

Practice point

Sentinel lymph node biopsy provides accurate staging of the lymph node basin by presenting a high-yield, low volume tissue sample for histopathological assessment. Not surprisingly, there is an increased rate of detection of micrometastatic disease when increasing numbers of sections are evaluated pathologically including when supplemented by immunohistochemistry for melanoma associated antigens. However there is no consensus as to the optimal number of sections that should be examined, the levels at which they should be cut from the paraffin block and which immunostains should be utilised.

Practice point

Sentinel lymph nodes (SLNs) should be removed intact, preferably with a thin rim of surrounding adipose tissue and be devoid of crush or diathermy artefacts that may complicate pathological assessment. The pathology request form should indicate the number of removed SLNs and their anatomical locations and the specimens clearly labelled. Any “second tier” lymph nodes or non-SLNs that have also been removed should be indicated as such on the request form and the specimens clearly labelled. The pathologist should slice the SLN using either the bivalving procedure along its longitudinal axis through the median plane or cut the SLN into multiple transverse slices using the “bread loaf” technique to make available the largest cut surface area of lymph node tissue for pathological examination. To identify low volume metastases, pathologists should examine multiple
Practice point

Haematoxylin-eosin and immunohistochemically-stained sections from each SLN. Sections from each slice of all SLNs should be stained with both H&E and immunohistochemistry for melanoma associated antigens. HMB-45, S100, SOX10, Melan A and tyrosinase have all been utilised as immunohistochemical stains. As per AJCC guidelines, in patients with positive SNs, the single largest maximum dimension (measured in millimeters to the nearest 0.1 mm using an ocular micrometer) of the largest discrete metastatic melanoma deposit should be recorded in the pathology report. Routine frozen section examination of SNs from melanoma patients is not recommended.

Back to top

2.1.4 What are the recommended safety margins for radical excision of a primary melanoma (in situ)?

<table>
<thead>
<tr>
<th>Evidence-based recommendation</th>
<th>Grade</th>
</tr>
</thead>
<tbody>
<tr>
<td>After initial excision biopsy, the radial excision margins, measured clinically from the edge of the melanoma, should be 5-10 mm (measured with good lighting and magnification) with the aim of achieving complete histological clearance. Melanoma in situ of non-lentigo maligna type is likely to be completely excised with 5mm margins whereas lentigo maligna may require wider excision. Minimum clearances from all margins should be stated/assessed. Consideration should be given to further excision if necessary; positive histological margins are unacceptable.</td>
<td>D</td>
</tr>
</tbody>
</table>

Practice point

Excisions should have vertical edges to ensure consistent margins.

Practice point

For all melanomas, minimum clearances from all margins should be stated/assessed. When necessary, further excision should be performed in order to achieve the appropriate margin of clearance.
**Practice point**

Excision biopsy of the complete lesion with a narrow (2mm) margin is appropriate for definitive diagnosis of primary melanoma. Once the diagnosis of melanoma has been made, re-excision of the lesion (biopsy site) should then be performed in order to achieve the definitive, wider margins that are recommended in these guidelines.

**Practice point**

Depth of excision in usual clinical practice is excision down to but not including the deep fascia unless it is involved or has been reached during the diagnostic excision. For body sites where there is particularly deep subcutis, it is usual practice to excise to a depth equal to the recommended lateral (radial) excision margins for that specific melanoma; in these cases it is not deemed necessary to excise right down to fascia.

**Practice point**

Where tissue flexibility is limited, a flap repair or skin graft may be necessary subsequent to an adequate margin of removal.

**Practice point**

Most primary melanomas can be treated as an outpatient under local anaesthesia or as a day-case.

**Practice point**

Patients should be informed that surgical excision may be followed by wound infection, bleeding, haematoma, failure of the skin graft or flap, risk of numbness, a non-cosmetic scar, dehiscence and the possibility of further surgery.
Practice point

Some tumours may be incompletely excised despite using the above-recommended margins. These include melanomas occurring in severely sun-damaged skin (e.g. LM) and those with difficult-to-define margins (eg amelanotic and desmoplastic melanomas). In these categories, the presence of atypical melanocytes at the margins of excision should be detected by comprehensive histological examination (including immunohistochemical staining) and followed by wider excision as appropriate. Alternatively, staged serial excision (also known as ‘slow Mohs’ surgery) may be utilised to achieve complete histological clearance of melanoma in situ/lentigo maligna. Pre-operative mapping of the extent of some lesions with confocal microscopy may be useful and is available in some centres. Referral to a specialist melanoma centre or discussion in a multidisciplinary meeting should be considered for difficult or complicated cases.

Practice point

Amelanotic melanoma can present significant difficulties for defining a margin with up to one third of subungual and nodular melanomas being non-pigmented. This may dictate choice of a wider margin, or further re-excision, where practicable.

Back to top

2.1.5 What are the recommended safety margins for radical excision of invasive melanomas?

<table>
<thead>
<tr>
<th>Evidence-based recommendation</th>
<th>Grade</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>(pT1) melanoma &lt; 1.0 mm</strong></td>
<td><strong>B</strong></td>
</tr>
<tr>
<td>After initial excision biopsy, the radial excision margins, measured clinically from the edge of the melanoma, should be 1 cm. Minimum clearances from all margins should be stated/assessed. Consideration should be given to further excision if necessary; positive histological margins are unacceptable.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Evidence-based recommendation</th>
<th>Grade</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>(pT2) melanoma 1.01 mm-2.00 mm</strong></td>
<td><strong>B</strong></td>
</tr>
<tr>
<td>After initial excision biopsy, the radial excision margins, measured clinically from the edge of the melanoma, should be 1-2 cm. Minimum clearances from all margins should be stated/assessed. Consideration should be given to further excision if necessary;</td>
<td></td>
</tr>
<tr>
<td>Evidence-based recommendation</td>
<td>Grade</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>-------</td>
</tr>
<tr>
<td>positive histological margins are unacceptable.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Evidence-based recommendation</th>
<th>Grade</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>(pT3) melanoma 2.01 mm–4.00 mm</strong>&lt;br&gt;After initial excision biopsy, the radial excision margins, measured clinically from the edge of the melanoma, should be 1–2 cm. Minimum clearances from all margins should be stated/assessed. Consideration should be given to further excision if necessary; positive histological margins are unacceptable. Caution should be exercised for melanomas 2.01–4.00 mm thick, especially with adverse prognostic factors, because evidence concerning optimal excision margins is unclear. Where possible, it may be desirable to take a wider margin (2 cm) for these tumours depending on the tumour site and characteristics, and prevailing surgeon/patient preferences.</td>
<td>B</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Evidence-based recommendation</th>
<th>Grade</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>(pT4) melanoma &gt; 4.0 mm</strong>&lt;br&gt;After initial excision biopsy, the radial excision margins, measured clinically from the edge of the melanoma, should be 2 cm. Minimum clearances from all margins should be stated/assessed. Consideration should be given to further excision if necessary; positive histological margins are unacceptable.</td>
<td>B</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Evidence-based recommendation</th>
<th>Grade</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acral lentiginous and subungual melanoma are usually treated with a minimum margin as set out above, where practicable, including partial digital amputation usually incorporating the joint immediately proximal to the melanoma.</td>
<td>D</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Evidence-based recommendation</th>
<th>Grade</th>
</tr>
</thead>
<tbody>
<tr>
<td>Excision margins might be modified to accommodate individual anatomic sites or functional considerations, but this practice would be based solely on case-series information, and individual factors, rather than RCT evidence which is currently lacking.</td>
<td>D</td>
</tr>
</tbody>
</table>
**Practice point**

Excisions should have vertical edges to ensure consistent margins.

**Practice point**

For all melanomas, minimum clearances from all margins should be stated/assessed. Consideration should be given to further excision if necessary because positive histological margins are unacceptable.

**Practice point**

Excision biopsy of the complete lesion with a narrow (2mm) margin is appropriate for the definitive diagnosis of primary melanoma. Once the diagnosis of melanoma has been made, re-excision of the lesion (biopsy site) should then be performed in order to achieve the definitive, wider margins that are recommended in these guidelines.

**Practice point**

Depth of excision in usual clinical practice is excision down to but not including the deep fascia unless it is involved or has been reached during the diagnostic excision. For body sites where there is particularly deep subcutis, it is usual practice to excise to a depth equal to the recommended lateral (radial) excision margins for that specific melanoma; in these cases it is not deemed necessary to excise right down to fascia.

**Practice point**

Where tissue flexibility is limited, a flap repair or skin graft is often necessary subsequent to an adequate margin of removal.

**Practice point**

Most primary melanomas can be treated as an outpatient under local anaesthesia or as a day-case.
Practice point

Patients should be informed that surgical excision may be followed by wound infection, bleeding, haematoma, failure of the skin graft or flap, risk of numbness, a non-cosmetic scar, dehiscence and the possibility of further surgery.

Practice point

Some tumours may be incompletely excised despite using the above-recommended margins. These include melanomas occurring in severely sun-damaged skin (e.g. lentigo maligna) and those with difficult-to-define margins (e.g. amelanotic and desmoplastic melanomas). In these categories, the presence of atypical melanocytes at the margins of excision should be detected by comprehensive histological examination (including immunohistochemical staining) and followed by wider excision.

Practice point

Amelanotic melanoma can present significant difficulties for defining a margin with up to one third of subungual and nodular melanomas being non-pigmented. This may dictate choice of a wider margin, or further re-excision, where practicable.

Practice point

For patients with deeper invasive melanomas (> 1 mm thick), referral to a specialised melanoma centre or discussion in a multidisciplinary meeting should be considered to ensure that best practice is implemented and for the collection of national outcome data. This may present logistic difficulties in regional and remote areas, but input from a specialist melanoma centre.

Back to top

2.1.6 What is the role of dermoscopy in melanoma diagnosis?

Practice point

Dermoscopy can also identify diagnostic features in non-pigmented (amelanotic) lesions.
Clinical practice guidelines for the diagnosis and management of melanoma

Evidence-based recommendation | Grade
---|---
Clinicians who are performing skin examinations for the purpose of detecting skin cancer should be trained in and use dermoscopy. | A

Back to top

2.1.7 What is the role of sequential digital dermoscopy imaging in melanoma diagnosis?

Practice point

Only flat or slightly raised lesions should undergo dermoscopy monitoring. Suspicious nodular lesions should not be monitored but should be excised.

Practice point

The interval for short-term monitoring is 3 months where any change leads to excision. Where lentigo maligna is in the differential diagnosis it is recommended an additional 3 months of monitoring performed, i.e. total of 6 months.

Practice point

The usual interval for long-term monitoring is 6-12 months. Unlike short-term monitoring, certain specific changes are required for excision to be indicated.

Evidence-based recommendation | Grade
---|---
To assess individual melanocytic lesions of concern, recommend the use of short-term sequential digital dermoscopy imaging (dermoscopy monitoring) to detect melanomas that lack dermoscopic features of melanoma. | B

Evidence-based recommendation

To assess individual or multiple melanocytic lesions in routine surveillance of high risk
2.1.8 What is the role of automated instruments in melanoma diagnosis?

**Evidence-based recommendation**

There is insufficient evidence to recommend the routine use of automated instruments for the clinical diagnosis of primary melanoma. However, particularly when a benign measurement is found using the cited protocols of Nevisense™ and MelaFind™, this information may aid the clinician.

Grade: D

2.1.9 What is the appropriate treatment of macroscopic (i.e. detectable clinically or by ultrasound) nodal metastases?

**Practice point**

Patients with macroscopic nodal disease should have the diagnosis confirmed preoperatively by image guided fine needle aspiration cytology and undergo staging with whole body PET-CT and MRI brain or CT Brain, Chest Abdomen and Pelvis.

**Practice point**

Patients with a parotid lymph node recurrence should undergo a superficial parotidectomy and upper neck dissection (levels 1B, 2, 3, and upper 5 and possibly 1a).

**Evidence-based recommendation**

Complete lymphadenectomy is recommended for patients with palpable or imaging detected lymph node field recurrence.

Grade: C
Practice point

Complete lymphadenectomy results in improved regional control over lesser procedures.

Practice point

All patients with Stage III B/C disease should be presented at a multidisciplinary management meeting.

Practice point

These high risk patients should be offered the opportunity to enrol in systemic adjuvant or neoadjuvant therapy trials.

Back to top

This guideline includes evidence-based recommendations (EBR), consensus-based recommendations (CBR) and practice points (PP) as defined in the table below. Recommendations and practice points were developed by working party members and sub-committee members.

Each EBR was assigned a grade by the expert working group, taking into account the volume, consistency, generalisability, applicability and clinical impact of the body of evidence according to NHMRC Level and Grades for Recommendations for Guidelines Developers.[1]

2.1.10 NHMRC approved recommendation types and definitions

<table>
<thead>
<tr>
<th>Type of recommendation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Evidence-based recommendation</td>
<td>A recommendation formulated after a systematic review of the evidence, indicating supporting references</td>
</tr>
<tr>
<td>Consensus-based recommendation</td>
<td>A recommendation formulated in the absence of quality evidence, after a systematic review of the evidence was conducted and failed to identify admissible evidence on the clinical question</td>
</tr>
<tr>
<td>Practice point</td>
<td>A recommendation on a subject that is outside the scope of the search strategy for the systematic review, based on expert opinion and formulated by a consensus process</td>
</tr>
</tbody>
</table>

2.2 References


2.1 Identification and management of high-risk individuals - Introduction

Intro required?

2.2 Genetic determinants of high risk

To be developed (non SR)

2.3 Validated models for overall measurements of high risk

Appendices
2.4 Interventions that benefit those at high risk of new primary melanomas

Appendices

2.5 Clinical features of melanoma

Supported by

Contents

1 Introduction
2 Classification of melanoma
3 Clinical presentations of melanoma subtypes
   3.1 Superficial spreading melanoma
   3.2 Nodular melanoma
   3.3 Lentigo maligna melanoma
   3.4 Desmoplastic melanoma
Clinical practice guidelines for the diagnosis and management of melanoma

3.5 Acralfentiginous and subungal melanoma
3.6 Spitzoid melanoma
4 Atypical clinical features
5 Dynamic features of melanomas
6 Evidence summary and recommendations
7 Conclusions
8 References
9 Appendices

2.5.1 Introduction

Whilst there is evidence that early detection of superficial spreading melanomas has improved, with a corresponding reduction in both median tumor thickness and melanoma mortality from this subtype,[1] a number of studies have also shown an increasing or stable incidence rate of thick melanomas.[2][3][4][5][6][7] Nodular, desmoplastic and acral lentiginous melanomas are often diagnosed when they are much thicker lesions compared to superficial spreading melanoma.[8][9][3][4][6][10] This is in part due to their atypical clinical presentation. Improved diagnostic accuracy of these subtypes can significantly improve mortality from melanoma.

Back to top

2.5.2 Classification of melanoma

Melanoma is currently classified into subtypes; superficial spreading (SSM), nodular melanoma (NM), lentigo maligna melanoma (LMM), acral lentiginous (ALM) and desmoplastic melanoma (DM), based on various morphologic and histologic characteristics.[11][12] SSM is the most common subtype accounting for approximately 55-60% of melanoma, and is characterised by a slow radial growth phase (months to years), (with pagetoid spread of atypical melanocytes within the epidermis, followed by invasion into the dermis. LMM accounts for approximately 10-15% of cases in Australia, occurring on sun damaged skin with a slow lentiginous (linear) proliferation of atypical melanocytes along the basal layer of the epidermis, commonly involving hair follicles and sweat ducts, which may be present for years prior to invasion. Acral lentiginous melanomas (which make up only 1-2% of cases in Australia) arise on glabrous skin and also have a prominent lentiginous radial growth component, but appear not to be causally associated with sun exposure. NM accounts for 10-15% of cases and differs from the other main subtypes by being uniformly invasive (early vertical growth) with a lack of epidermal involvement (radial growth) beyond 3 rete ridges. Desmoplastic melanomas account for 1-2% of cases in Australia and are characterized by malignant spindled melanocytes with surrounding fibrous stroma. They can be difficult to diagnose both clinically and on histopathology.

Back to top

2.5.3 Clinical presentations of melanoma subtypes

As well as having distinct histopathology, melanoma subtypes differ in their clinical presentation.
2.5.3.1 Superficial spreading melanoma

SSM is more common in younger patients and tends to occur on the trunk of naevus prone individuals and has a strong relationship with intermittent sun exposure. It presents as an Asymmetrical pigmented lesion with irregular Borders, Colour variation, typically of larger Diameter (the ABCD rule). Macroscopically, it tends to stand out as an ‘ugly duckling’. Common specific dermoscopic features are branched streaks or pseudopods, blue-grey veil, multiple irregular brown dots or globules, regression features, inverse or broadened network and atypical/polyomorphous vessels.

2.5.3.2 Nodular melanoma

Whilst NM account for only 10-15% of melanomas in Australia, they contribute disproportionately to melanoma deaths. In contrast to SSM, NM does not conform to the ABCD rule, but is more often a symmetrical, dome shaped, hypomelanotic lesion. The EFG aide memoire reminds us that they are often Elevated, Firm and Growing. NM may therefore masquerade as basal or squamous cell carcinomas or angiomas. Many NM appear to the patient to be without pigment but closer inspection will reveal light pigmentation in some and focal pigmentation in others. Dermoscopy will show melanin pigment in 90% of NM although 27% in one large series were lightly or focally pigmented and 9.6% were completely amelanotic. Dermoscopic features seen in other subtypes are less common, but, blue-white veil, blue areas, black areas, milky pink areas, atypical vessels, and symmetry of pigment pattern are more commonly identified. NM is more commonly found on severely sun damaged sites such as the head and neck of older individuals and is less commonly associated with large numbers of naevi. NM tend to exhibit more rapid vertical growth compared to SSM and LMM, and are much thicker at diagnosis.

2.5.3.3 Lentigo maligna melanoma

Lentigo Maligna (in-situ disease) may be present for months to years before invasion occurs. These lesions usually present as an asymmetrical pigmented macule which may occasionally be amelanotic (pink). Dermoscopic clues can be subtle, and include asymmetrical perifollicular pigmentation, grey and black dots (annular granular structures) and rhomboidal structures.

LMM (invasive disease) typically occurs on the head and neck of older patients and is associated with other signs of chronic sun exposure, such as solar lentigines, solar keratoses and non-melanoma skin cancer.

2.5.3.4 Desmoplastic melanoma

Desmoplastic melanoma also typically occurs on chronically sun-damaged skin, typically the head and neck, including the lip, nose and ears. It may arise de novo, or in association with a pre-existing lentigo maligna. It is more often amelanotic, firm or scar like in appearance. Dermoscopy is less useful in diagnosing DM unless features of an associated radial growth phase melanoma are present. It may be misdiagnosed clinically as a dermatofibroma, scar or non-melanoma skin cancer. Recurrence at the site of a previous biopsy diagnosed as benign on histopathology (e.g. as dermatofibroma, neurofibroma, scar) is not an uncommon presentation of DM as the histopathology can be difficult in some cases, particularly with partial biopsy. Review of previous pathology can be helpful where there is clinical suspicion.
2.5.3.5 Acral lentiginous and subungual melanoma

Acral lentiginous melanoma may arise de novo or from a pre-existing naevus and occurs more commonly on the sole than on the the palm. ALM may also arise from the nail apparatus (subungual melanoma). They may have a prolonged radial growth phase (similar to LMM) before becoming invasive. ALM typically presents with light asymmetric macular pigmentation, which may be patchy and therefore mistaken for a stain or bruise. Over 30% of cases are hypomelanotic.\[^{17}\] It has a predominant parallel ridge pattern on dermoscopy. Occasionally ALM can be verrucous and, particularly if hypomelanotic, may mimic plantar warts or tinea infection. If pared down, an ALM would not show the typical pinpoint vessels of a wart.

Subungual melanoma typically presents as longitudinal melanonychia (full length longitudinal brown to black pigment band arising from the nail matrix). This band typically broadens over time and dermoscopically one can observe streaks within the band with variable colour, thickness and spacing. Pigmentation of the proximal or lateral nail fold (Hutchinson’s sign) may be present. Growth of the tumour may cause nail dystrophy and eventual destruction of the nail plate. Subungual haematoma is a common differential diagnosis and may be distinguished by the presence of multiple reddish globules at the periphery of the pigmented area. These will grow out when observed over months. Bleeding within a tumour may occur, however, and the presence of subungal blood can not be used to rule out melanoma.\[^{18}\] Hypomelanotic subungual melanoma may present as a nail dystrophy and readily be mistaken for nail trauma or infection.

2.5.3.6 Spitzoid melanoma

Spitzoid melanoma is at the malignant end of the spectrum of melanocytic lesions which includes Spitz naevus and atypical Spitz tumour. The typical benign Spitz naevus occurs in the young (usually <20) presenting as a pink dome-shaped symmetrical papule with a well defined border (10% are pigmented). Atypical Spitz tumour and spitzoid melanoma tend to present as larger lesions, often asymmetrical with more irregular border and surface, and pink to variegated, at any age but usually >10.\[^{19}\][\(^{20}\] Spitz type lesions are defined by their histomorphology with large epithelioid and/or spindling melanocytes. Pathological assessment of these tumors is challenging and expert histopathological review should be considered prior to definitive surgical management. Partial biopsy is particularly unreliable with Spitz lesions. As yet there are no definitive molecular markers to assist diagnosis but this area is developing.

Back to top

2.5.4 Atypical clinical features

Melanoma may not conform to the usual ABCD criteria. They may be symmetric, dome shaped and skin coloured. Any lesion that is Elevated, Firm and Growing over a period of more than one month should raise suspicion for melanoma.
Lack of pigment is significantly associated with poorer diagnostic accuracy.\textsuperscript{[21]} Up to 20% of all melanomas are only partially pigmented (hypomelanotic), with true amelanosis much less common.\textsuperscript{[22],[23]} Nodular, desmoplastic and ALM subtypes are more commonly hypomelanotic (over 40% of cases) compared to SSM and LMM subtypes (approximately 10-25% of cases).\textsuperscript{[15],[23],[17]} Hypomelanotic melanomas may mimic basal cell carcinoma clinically, with a slightly shiny surface and atypical vessels on dermoscopy. Other dermoscopic clues include scar-like depigmentation, inverse network, irregular blue grey dots, blue-white veil and milky pink areas.\textsuperscript{[22],[24]} Whilst dermoscopic sensitivity is around 90% for pigmented lesions, it is much lower for predominantly amelanotic lesions.

Tumor thickness is not necessarily related to diagnostic delay.\textsuperscript{[2],[25],[26],[27]} Whilst some melanomas grow slowly over a number of years, others will become thick and life-threatening over weeks to months. More rapid growth has been associated with NM and desmoplastic subtypes as well as amelanosis.\textsuperscript{[16],[28],[29],[30]} These subtypes are more common on chronically sun damaged skin, typically on the head and neck and predominantly in older males.\textsuperscript{[9]}

Back to top

2.5.5 Dynamic features of melanomas

Perhaps the most helpful clinical feature of melanomas is that biologically significant melanomas are changing, regardless of their other clinical features. If these changes have been accurately perceived by the patient or there is photographic evidence to demonstrate stability or change, this may be very helpful in determining the right index of suspicion. Radial growth phase melanomas change in size, shape or colour and vertical growth phase melanomas elevation, ulceration and may bleed. A history of the duration of a lesion and any change within it is a minimum requirement for the assessment of any potential skin cancer.

Back to top

2.5.6 Evidence summary and recommendations

<table>
<thead>
<tr>
<th>Evidence summary</th>
<th>Level</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>NM, ALM and desmoplastic subtypes more commonly present as thick lesions and improved diagnostic accuracy of these is therefore critical.</td>
<td>III-2, III-3, IV</td>
<td>[10], [6], [9], [7], [4], [3]</td>
</tr>
<tr>
<td>Nodular melanomas are associated with more rapid vertical growth compared to superficial spreading melanomas.</td>
<td>III-3, IV</td>
<td>[28], [16], [29], [30]</td>
</tr>
<tr>
<td>Up to 20% of all melanomas are amelanotic or only partially pigmented, with this being more common amongst NM, ALM and desmoplastic subtypes.</td>
<td>IV</td>
<td>[15], [17], [23]</td>
</tr>
<tr>
<td>Amelanosis/hypomelanosis is significantly associated with poorer diagnostic</td>
<td>III-2,</td>
<td>[21], [22]</td>
</tr>
</tbody>
</table>


Clinical practice guidelines for the diagnosis and management of melanoma


Back to top
2.5.1 Diagnostic aids for melanoma

Introduction

There are many instruments available to aid the diagnosis of primary melanoma of the skin. We have reviewed the main techniques that have an adequate literature to propose recommendations, but understand that a variety of devices have not been reviewed.

The sections covers the following questions:

- What is the role of dermoscopy in melanoma diagnosis?
- What is the role of sequential digital dermoscopy imaging in melanoma diagnosis?
- What is the role of automated instruments in melanoma diagnosis?
- What is the role of confocal microscopy in melanoma diagnosis?

A systematic review on total body photography is underway and will be added to this section in due course.

2.5.2 Dermoscopy

Supported by
2.5.2.1 Background

Dermoscopy (dermatoscopy, surface microscopy, epiluminescence microscopy) is a technique that uses a hand-held magnifying device combined with either the application of a liquid between the transparent plate of the device and the skin, or the use of cross-polarised light. This technique allows the visualisation of diagnostic features of pigmented skin lesions that are not seen with the naked eye.\(^1\)\(^2\)\(^3\)\(^4\)

2.5.2.2 Summary of systematic review results

Meta-analyses performed on studies in a variety of clinical and experimental settings have shown that using dermoscopy improves diagnostic accuracy for melanoma.\(^5\)\(^6\) From a meta-analysis of nine level II diagnostic studies subject to varying degrees of verification bias performed prospectively in a clinical setting\(^7\)\(^8\)\(^9\)\(^10\)\(^11\)\(^12\)\(^13\)\(^14\)\(^15\)\(^16\) the diagnostic accuracy for melanoma, as expressed by the relative diagnostic odds ratio, was 15.6 (95% CI 2.9–83.7) times higher for dermoscopy compared with naked eye (clinical) examination.\(^17\) Importantly, the meta-analysis was restricted to studies that directly compared the two methods within each study. Sensitivity of dermoscopy was 18% (95% CI 9%–27%; P=0.002) higher than for naked eye examination, but there was no evidence of an effect on specificity (9% higher for dermoscopy; P=0.18).\(^17\) Subsequent to this meta-analysis one level II study has been published in a primary care setting showing results consistent with the meta-analysis (42% increase in sensitivity and 5% increase in specificity with dermoscopy compared to naked eye).\(^18\) However, there was a significant improvement in the confidence of diagnosis of both true melanoma (17% increase) and true non-melanoma (16% increase) with dermoscopy. In a further randomized clinical trial in primary care of both pigmented and non-pigmented lesions the odds ratio for a correct diagnosis in the dermoscopy compared to naked eye group was 1.51 (95% CI:0.96-2.37, p=0.07). Again, consistent with the meta-analysis, the effect was greater for the diagnosis of melanoma (61.5% sensitivity using dermoscopy versus 22.2% for naked-eye).\(^19\)

Specificity can also be examined by its effect on excision rates of benign lesions, which was not addressed in the meta-analysis. Two such studies suggest reduced rates of excision of benign lesions using dermoscopy (reduced benign to malignant ratio of excised lesions and reduction of patients referred to biopsy) and provide indirect evidence for improved specificity in a specialist setting.\(^8\)\(^9\) The addition of dermoscopy to naked eye (clinical) examination has also been shown to reduce excisions of benign pigmented lesions in high-risk patients in a specialist setting\(^20\) and routinely managed pigmented lesions in primary care.\(^18\)\(^19\)
While there are fewer studies on dermoscopy in primary care (general practice), all five that were undertaken in this context (one study with both general practitioners and inexperienced specialists or trainees)\cite{21} show a consistently improved sensitivity for the diagnosis of melanoma or the identification of suspicious lesions requiring biopsy.\cite{7,18,19,21,22} It should be noted that all the studies cited were undertaken by clinicians with some training in dermoscopy (restricted to lectures or reading material in some studies). For this reason, and based on other evidence where lack of training can lead to a reduction of diagnostic accuracy,\cite{23} some formal training in dermoscopy is required to achieve improvement in diagnostic accuracy.

**Practice point**

Dermoscopy can also identify diagnostic features in non-pigmented (amelanotic) lesions.

Back to top

### 2.5.2.3 Evidence summary and recommendations

<table>
<thead>
<tr>
<th>Evidence summary</th>
<th>Level</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>From a meta-analysis of nine level II studies prospectively performed in a clinical setting, the diagnostic accuracy for melanoma, as expressed by the relative diagnostic odds ratio, was 15.6 times higher for dermoscopy compared with naked eye examination. Sensitivity of dermoscopy was 18% (95% CI 9%-27%; P=0.002) higher than for eye examination, but there was no evidence of an effect on specificity. Two subsequent level II studies showed results consistent with the larger meta-analysis.(^+)</td>
<td>I, II</td>
<td>[7], [8], [9], [10], [11], [12], [13], [14], [15], [16], [17], [18], [19]</td>
</tr>
<tr>
<td>Dermoscopy has been shown to reduce the benign:malignant ratio of excised melanocytic lesions and reduce the number of patients referred for biopsy in both specialists and primary care.(^+)</td>
<td>II</td>
<td>[8], [9], [18], [20]</td>
</tr>
</tbody>
</table>

\(^+\)The studies were classified as III-2 according the NHMRC 2009 levels and grade of evidence. Using the Grade approach, the studies were then upgraded to level II if the only criteria not meeting level II was the pathologist was not blinded to clinical information of the patient/lesion since it is established that clinical information is required for an accurate pathological diagnosis of melanocytic lesions.
2.5.2.3.1 Recommendations

<table>
<thead>
<tr>
<th>Evidence-based recommendation</th>
<th>Grade</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinicians who are performing skin examinations for the purpose of detecting skin cancer should be trained in and use dermoscopy.</td>
<td>A</td>
</tr>
</tbody>
</table>

Back to top

2.5.2.4 References


Clinical practice guidelines for the diagnosis and management of melanoma


Back to top

2.5.2.5 Appendices

2.5.3 Sequential digital dermoscopy imaging

Supported by

Contents

1 Background
2 Summary of systematic review results
3 Evidence summary and recommendations
   3.1 Recommendations
4 References
2.5.3.1 Background

Sequential digital dermoscopy imaging (SDDI) or dermoscopy monitoring involves the capture and assessment of successive dermoscopic images, separated by an interval of time, of one or many melanocytic lesions to detect suspicious change.

This is performed in two settings: short-term dermoscopy monitoring (over a period of 3 months) for suspicious melanocytic lesions without evidence of melanoma, and long-term monitoring for surveillance (usually at intervals of 6-12 months). Long-term monitoring is generally used in the surveillance of high-risk patients, usually with multiple dysplastic naevi. In contrast, short-term monitoring of individual suspicious naevi can be used in any patient setting (eg. mildly atypical lesions with a patient history of change or moderately atypical lesions with a patient history of no change).

Back to top

2.5.3.2 Summary of systematic review results

In one study the sensitivity for the diagnosis of melanoma using short-term dermoscopy monitoring was 94% (excluding lentigo maligna which requires longer interval monitoring) and the specificity 84%. For long-term monitoring, three studies have shown a high specificity (95-96%) for the diagnosis of melanoma, but the sensitivity was not evaluated.

Four level II studies with more recent cohort studies all conducted in a specialist setting show consistently that SDDI allows the detection of melanoma that lack dermoscopic evidence of malignancy. Furthermore, the impact of routinely using SDDI has been shown in multiple studies to be high in regards to the proportion of melanomas detected by the technique. In three studies (two prospective observational trials and one retrospective cohort) of moderate-high risk patients in a specialist setting, SDDI allowed the detection of 34-61% of the patients' melanomas, in two studies (one prospective observational trial and one retrospective cohort) in routine dermatological practice between 12-55% of melanomas detected and in 52% in a self-referring dermoscopy telemedicine setting (retrospective study). Short-term SDDI allowed the detection of 33% of the patients' melanomas in a clinical trial of primary care physicians, however routine long-term SDDI of multiple naevi in lower risk patients is less efficacious. Finally, SDDI has been shown in two prospective observational trials in both a specialist (both short and long-term monitoring) and primary care setting (short-term monitoring) to significantly reduce the benign:melanoma excision ratio and the number of excised benign melanocytic lesions.
Practice point

Only flat or slightly raised lesions should undergo dermoscopy monitoring. Nodular lesions should not be monitored.

Practice point

The interval for short-term monitoring is 3 months where any change leads to excision. Where lentigo maligna is in the differential diagnosis it is recommended an additional 3 months of monitoring performed, i.e. total of 6 months.

Practice point

The usual interval for long-term monitoring is 6-12 months. Unlike short-term monitoring, certain specific changes are required for excision to be indicated.

2.5.3.3 Evidence summary and recommendations

<table>
<thead>
<tr>
<th>Evidence summary</th>
<th>Level</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Four level II studies and more recent cohort studies show consistently that sequential digital dermoscopic imaging (SDDI) allows the detection of suspicious dermoscopic change in melanomas that lack dermoscopic evidence of melanoma at a particular time.</td>
<td>II, III-2</td>
<td>[1], [4], [7], [5], [3], [8]</td>
</tr>
<tr>
<td>The routine use of SDDI in both specialist and primary care allows the detection of a significant proportion of patients’ melanomas. Long-term SDDI of multiple naevi in lower risk patients, while allowing detection of melanoma, is less efficacious.</td>
<td>II, III-2</td>
<td>[13], [4], [8], [10], [9], [11], [14], [15], [16]</td>
</tr>
<tr>
<td>SDDI has been shown to reduce the benign:malignant ratio of excised melanocytic lesions and reduce the number of patients referred for biopsy in both specialists and primary care.</td>
<td>II</td>
<td>[13], [11]</td>
</tr>
</tbody>
</table>
2.5.3.3.1 Recommendations

<table>
<thead>
<tr>
<th>Evidence-based recommendation</th>
<th>Grade</th>
</tr>
</thead>
<tbody>
<tr>
<td>To assess individual melanocytic lesions of concern, recommend the use of short-term sequential digital dermoscopy imaging (dermoscopy monitoring) to detect melanomas that lack dermoscopic features of melanoma.</td>
<td>B</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Evidence-based recommendation</th>
<th>Grade</th>
</tr>
</thead>
<tbody>
<tr>
<td>To assess individual or multiple melanocytic lesions in routine surveillance of high risk patients, recommend the use of long-term sequential digital dermoscopy imaging (dermoscopy monitoring) to detect melanomas that lack dermoscopic features of melanoma.</td>
<td>B</td>
</tr>
</tbody>
</table>

Back to top

2.5.3.4 References


Back to top
2.5.4 Automated instruments

An automated diagnostic instrument is defined as one that requires minimal or no input from the clinician to achieve a diagnosis. Each automated instrument offers different technology with differing diagnostic ability. Guidelines for assessing such instruments have been published.\(^1\) To date, only 2 studies have been reported comparing clinician diagnosis or management with machine diagnosis with an adequate sample size to assess both specificity and sensitivity for the diagnosis of melanoma.\(^2\)

Back to top
2.5.4.2 Summary of systematic review results

The MelaFind™ system, a digital multispectral image analysis device for the use on suspicious pigmented melanocytic lesions, was directly compared to specialists’ diagnosis in a prospective multicentre clinical trial. Here, lesions were recruited (analysed) if they were scheduled for biopsy, usually because of clinician concern. The measured sensitivity of MelaFind™ was 98.4% (125 of 127 melanomas; 95%CI 95.6-) which achieved the pre-trial primary aim and had a superior specificity (9.9%) to clinicians’ (3.7%); p=0.02.

The Nevisense™ system, an electrical impedance device for the use on lesions, irrespective of pigmentation, where a diagnosis of melanoma needs exclusion, underwent a prospective multicentre clinical trial in a specialist setting. The observed sensitivity of Nevisense™ was 96.6% (256 of 265 melanomas; 95% CI 94.2-) with an observed specificity of 34.4%. Again, lesions were recruited if they were scheduled for biopsy, but a direct comparison with the recruiting clinician’s diagnosis was not performed.

In both of the above systems high false positive rates with the highly prevalent seborrhoeic keratoses may cause a significantly poorer specificity when used by non-experts in the field. This has yet to be investigated. Indeed, currently there is no data on the use of these instruments in clinical trials in a primary care setting.

The effect of adding the MoleMate™ system, a digital image analysis device, to suspicious pigmented lesions in primary care, was assessed in a multicentre randomised clinical trial. The primary endpoint was the effect of the device on the proportion of appropriately referred lesions, where the secondary care experts decided to biopsy or monitor, which did not differ significantly between those lesions being measured by the device (56.8% 130/229) or not (64.5% 111/172); p=0.12. The proportion of benign lesions appropriately managed and the percentage agreement with an expert decision to biopsy or monitor also did not significantly differ between use and non-use of the device. 18/18 melanomas were appropriately referred in the intervention group and 17/18 in the control group.

Back to top

2.5.4.3 Evidence summary and recommendations

<table>
<thead>
<tr>
<th>Evidence summary</th>
<th>Level</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>To date, only 2 studies have been reported comparing specialist clinician diagnosis with an automated machine diagnosis with an adequate sample size to assess both specificity and sensitivity for the diagnosis of melanoma.</td>
<td>II</td>
<td>[2], [5]</td>
</tr>
</tbody>
</table>
2.5.4.3.1 Recommendations

<table>
<thead>
<tr>
<th>Evidence-based recommendation</th>
<th>Grade</th>
</tr>
</thead>
<tbody>
<tr>
<td>There is insufficient evidence to recommend the routine use of automated instruments for the clinical diagnosis of primary melanoma. However, particularly when a benign measurement is found using the cited protocols of Nevisense™ and MelaFind™, this information may aid the clinician.</td>
<td>D</td>
</tr>
</tbody>
</table>

2.5.4.4 References


2.5.4.5 Appendices
2.5.5 Confocal microscopy

2.5.5.1 Reflectance confocal microscopy

In vivo reflectance confocal microscopy (RCM) is a non-invasive technique that allows examination of the skin with cellular resolution. A systematic literature search up to 24 December 2015 reports on a total of 21 studies involving 3108 patients with a total of 3602 lesions included in the per-lesion analysis: The corresponding pooled results for sensitivity and specificity were 93.6% (95% CI: 0.92-0.95) and 82.7% (95% CI: 0.81-0.84) respectively for the diagnosis of malignant lesions. Positive likelihood ratio and negative likelihood ratio were 5.84 (95% CI: 4.27-7.98) and 0.08 (95% CI: 0.07-0.10) respectively. Subgroup analysis showed that RCM had a sensitivity of 92.7% (95% CI: 0.90-0.95) and a specificity of 78.3% (95% CI: 0.76-0.81) for detecting melanoma.

In May 2015 the Diagnostics Advisory Committee of the National Institute for Health and Care Excellence (NICE), UK reviewed the evidence available.\(^{[2]}\)

The Committee considered the quality of the studies included in the systematic review of clinical effectiveness and concluded that studies from 2013 onwards were most relevant to the assessment.\(^{[1]}\) Concerning studies focused on melanoma diagnosis, the following were considered the most relevant: Alarcon et al. (2014)\(^{[3]}\), Pellacani et al. (2014)\(^{[4]}\), Ferrari et al. (2014)\(^{[5]}\), Stanganelli et al. (2014)\(^{[6]}\), and Rao et al. (2013)\(^{[7]}\).

The Committee considered the evidence on using the VivaScope systems after dermoscopy, to rule out biopsy and excision of equivocal skin lesions in people with suspected melanoma reported similar sensitivity values, but higher specificity values for the VivaScope systems compared with dermoscopy alone. The Committee concluded that the evidence suggested that imaging using the VivaScope systems after dermoscopy had a higher negative predictive value than dermoscopy alone.\(^{[1]}\) In term of cost/time efficiency, it seems to save over 50% of benign lesions from unnecessary excision.\(^{[3]}\)\(^{[4]}\)\(^{[8]}\)\(^{[9]}\)

Lesions located on the head and neck, damaged by chronic sun-exposure\(^{[10]}\)\(^{[11]}\), lesions dermoscopically typified by regression\(^{[12]}\) and amelanotic tumors\(^{[13]}\)\(^{[14]}\) represent the best indications for the use of RCM.

The Committee also considered evidence on the use of VivaScope systems to image different types of lesion.\(^{[2]}\) The Committee noted that there is a lack of available evidence on using the VivaScope systems in diagnosing lentigo maligna (LM) and in defining lesion margins in melanoma. Clinical experts noted that VivaScope is not useful in clinical practice for defining lesion margins in melanoma as the margins of melanomas are clearly defined and can easily be completely excised.
2.5.5.2 References


Back to top

2.5.6 Skin surface imaging (total body photography)

Appendices

View recommendation components

View pending evidence

View body of evidence

View all comments

View literature search

Back to top

2.6 Biopsy of suspicious lesion
2.6.1 Background

Biopsy of a suspicious pigmented lesion aims to establish a diagnosis and to stage the tumour for planning definitive surgical therapy. In addition, an excisional biopsy may completely remove the tumour. Different methods of biopsy are variably effective in achieving these goals and it is important to choose the most appropriate method according to the aims of the biopsy, the site and size of the lesion, the index of suspicion for melanoma, the likelihood of invasive tumour, and patient factors including comorbidities, cosmesis and age.

Back to top

2.6.2 Summary of systematic review results

2.6.2.1 Complete excisional biopsies

2.6.2.1.1 Elliptical Excision and Primary Closure

The ideal method for skin lesions suspected of being melanoma is complete excision with a 2 mm margin. An ellipse specimen should follow the lines of relaxed skin tension with the deep margin in subcutis. Primary closure is the preferred method of closure following excisional biopsy and skin flaps or grafts should be avoided because these may compromise the definitive re-excision.

Complete excision best facilitates accurate diagnosis and microstaging compared to partial biopsy techniques.\[1\]

Back to top
2.6.2.1.2 Deep Shave excision (Saucerisation) and punch excision

Deep shave excision (Saucerisation, scoop shave excision) and punch excision methods (e.g. 5 mm punch for a 3 mm lesion) may also be used for complete excision but are more often associated with positive margins than elliptical excision and primary closure.[2] Deep shave excision may be defined as a shave excision that aims to completely remove the lesion both peripherally and in depth. However, skill and practice are required to perform the procedure effectively.

Attempts at deep shave excision will more often completely remove thin melanomas and are more likely to transect the tumour margins with increasing tumour thickness.[2][1] Transection of the tumour base will lead to loss of limited amounts of residual tumour that may be destroyed by inflammation and wound healing and may undermine the capacity to accurately assess tumour depth for prognostication, accurate staging and treatment planning.

Deep shave excision is becoming more widely used and in most recent studies was the dominant mode of biopsy for melanoma, particularly by dermatologists worldwide. Transection of the tumour base has been shown to be common with shave biopsy in recent studies (68%, 32%, 62%, 65%, 9%, 37% in studies from Egnatios,[3] Hieken,[4] Lowe,[5] Mills,[6] Mir[2] and Zager[7] respectively), though the extent to which these shaves were attempting to completely remove the tumour were generally not stated.

Deep shave excision has the advantages of being relatively speedy, inexpensive and requiring little equipment or staff assistance. The procedure thus allows the conduct of greater numbers of biopsies, including lesions with lower indices of suspicion. Delays are minimized in the conduct of biopsy procedures as many deep shaves are conducted as part of the consultation and do not require another appointment. The technique requires careful lesion selection and expertise in conduct to avoid base transection, a serious and too frequently evident drawback with use of this method. In general the technique should be limited to non-palpable lesions. If a clinician cannot be confident of complete removal of the deepest part of the lesion a full excisional biopsy should be undertaken.

Back to top

2.6.2.1.3 Partial biopsies

Methods of partial biopsy that have been assessed include partial punch biopsy, shave biopsy and, to a lesser extent, incisional biopsy. At times partial biopsy may be the most appropriate mode of biopsy for large lesions, those on acral sites or other difficult locations where an excisional biopsy may have unwanted functional or cosmetic outcomes or in patients with significant comorbidities.

The most important outcome of a partial biopsy is accurate diagnosis. One large study has compared melanoma biopsy methods for the detection of melanoma.[1] This study showed that punch biopsy is associated with a false negative diagnosis rate of 23.3% compared with 4.5% for all shave biopsies and 1.7% for excisional biopsy. Adverse outcomes with persistence or progression of disease followed 11.6% of false negative diagnoses on punch biopsy and 1.7% following shave biopsy. Most of these false negative diagnoses and
adverse outcomes would have been avoided if all lesions clinically suspected as melanoma that had then been shown to be melanocytic on biopsy had been immediately subjected to excisional biopsy. Most (78%) of incorrect diagnoses made on small punch biopsies were attributable to errors in histopathological interpretation and the remainder appeared to be due to sampling error. Partial biopsies may lead to pathological incorrect interpretation because it is not possible to assess important diagnostic criteria when the whole lesion is no longer available for assessment.

Accurate staging of the tumour on partial biopsy permits prognostication and planning of appropriate surgical therapy for the primary tumour. Understaging of melanoma as a result of partial biopsy has been examined in multiple studies. Increases in tumour thickness on assessment of residual melanoma in wide local excision (WLE) after a partial biopsy were shown after 3.5%-44% of shave and 34%-38% of punch biopsies,\cite{8,6,9,10}. The variation may be explained by differing intentions on the part of the clinicians to partially or completely remove the tumour in the initial biopsy procedure.

Sufficient change in tumour thickness to upgrade the T-stage on WLE has been reported in 7%-34% of punch biopsies and 3%-19% of shave biopsies,\cite{1,9,10,6,3,4,7}

Upgrades to T-stages resulted in additional surgical therapy in 3.3%-5% of shave biopsies,\cite{1,4,10} and 18% of punch biopsies.\cite{7}

Not all understaging of melanoma may be evident on the subsequent wide excision as diathermy used in the procedure or destruction of tumour by inflammation may destroy underlying tumour in the biopsy bed.

Deep shave excision (saucerisation) should be distinguished from superficial shave techniques which are generally used for partial biopsy. The latter are most appropriately applied to flat lesions that appear to be in situ. Shave biopsies of all types have been shown to be associated with very high rates of transection (64-65%) of the tumour base in some studies.\cite{6,5} When shave excision is applied to thin melanomas (<1.0 mm in tumour thickness), rates of base transection are much lower (9-21%)\cite{2,9} with very few melanomas upstaged on WLE. Several studies have shown a relationship between base transection and increasing tumour thickness.\cite{10,2,1} These studies do not distinguish attempts at deep shave excision from superficial shave for partial biopsy.

Survival and the performance and outcomes of sentinel node biopsy show no differences according to partial versus complete excisional biopsy type.\cite{11,5,6,12,13,7}

There are no studies to date of the morbidity and cosmetic outcomes associated with different biopsy types.

All partial biopsies should include the most suspicious or invasive areas of the lesion. Dermoscopy or confocal microscopy may be helpful in targeting the most suspicious area.

It may be appropriate to indicate in the pathology report that a partial biopsy may not be fully representative of the lesion.

Partial biopsies are an important cause of litigation in the USA because of inadequate material being available for analysis by the pathologist.\cite{14}
Naevoid melanomas and desmoplastic melanomas may be extremely difficult to diagnose histopathologically, particularly on a small biopsy.

It is important to consider the weaknesses of partial biopsies when interpreting the pathologist’s report. If the result does not accord with the clinical impression or there is diagnostic uncertainty, an additional sample should be obtained, preferably by performing a complete excision. This is especially important when the histopathological diagnosis from a partial biopsy is of a melanocytic lesion.

Back to top

2.6.2.2 Clinical information for the pathology request to facilitate accurate histopathological diagnosis

All biopsy requests should include information on history of lesional changes, site of the lesion, age and gender of the patient and previous melanoma history. Any previous trauma or attempted therapeutic intervention to the lesion should be noted. If possible, the provision of clinical and dermoscopic images to the pathologist have been shown to enhance accuracy of histopathological diagnosis.[15]

The biopsy type and proportion of the lesion sampled should be indicated. Focally suspicious areas within a larger lesion can be indicated on a diagram or photograph or marked for the pathologist e.g. with superficial punch incision.[16]

Back to top

2.6.2.2.1 Indications for different modes of partial biopsy

Partial incisional or shave biopsies may be appropriate in the hands of experienced clinicians and in carefully selected clinical circumstances, such as large in situ or for large facial or acral lesions or where the suspicion of melanoma is low.

An incisional, partial punch biopsy provides dermis and often subcutis for assessment of tumour thickness but samples only a limited width of the lesion and is therefore prone to sampling error as well as diagnostic error. Punch biopsy should be avoided if there is any possibility of melanoma because of the high rates of false negative diagnosis demonstrated with partial punch technique. Multiple punch biopsies may reduce error in selected cases.

A broad superficial shave biopsy can provide a larger area of epidermis for histopathology and is often a useful diagnostic technique for large superficial lesions, but often fails to include sufficient dermis for the assessment of deeper parts of lesions with a significant dermal component. These biopsies may be considered for lesions that are likely to be confined to the epidermis (e.g. when attempting to differentiate in-situ melanoma from solar lentigo or seborrheic keratosis or a flat acquired melanocytic naevus). In order to maintain the integrity of the epidermis on the sample, at least papillary dermis must be present across the shave. Superficial shave biopsies taken through papillary dermis heal with little or no scar and are therefore suitable for use on the face. A photograph to identify the biopsy site should be used for superficial shave biopsies in cases for which it may not be possible to identify the biopsy site when it has healed.
Incisional biopsy removing as much of the lesion as is feasible or the most invasive or suspicious part can be a very useful method of partial biopsy in larger tumours.

Frozen section and cytological analysis are inappropriate for suspicious pigmented lesions, but may be of value (particularly fine needle biopsy cytology) when assessing potential metastases from a melanoma, for example, in a lymph node or subcutaneous tissue.

When clinical suspicion of malignancy is low and there is no elevation or induration to suggest possible invasive melanoma, short term observation for 3-6 months may be appropriate, preferably backed up by a dermoscopic image, a clinical image and an accurate description and measurement of the lesion.[17]

Referral to a specialist should be considered before biopsy for lesions in technically difficult anatomical locations (e.g. the eyelid) or where the operator is not confident in achieving an adequate sample or good cosmetic result. The specialist to whom the referral is being made should be advised directly of the degree of urgency.

Where clinical suspicion remains despite a negative pathology report following a partial biopsy, re-biopsy or excision should be performed. Even after complete excision, if the pathology result does not correlate with the clinical impression, discussion of the case with the pathologist is recommended. Review of the slides by a second pathologist may be appropriate if clinical suspicion remains or if there is diagnostic uncertainty.

2.6.3 Evidence summary and recommendations

<table>
<thead>
<tr>
<th>Evidence summary</th>
<th>Level</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Partial biopsies versus completeness of excision</strong></td>
<td>III-2</td>
<td>[1]</td>
</tr>
<tr>
<td>Complete excision with a 2mm margin is the most reliable diagnostic biopsy method for skin lesions suspected of being melanoma.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Punch biopsy has been shown in one large study to be associated with high rates of false negative histopathological diagnosis of 23% and should be used with caution for melanocytic lesions.</td>
<td>III-2</td>
<td>[1]</td>
</tr>
<tr>
<td>Deep shave excision (saucerisation) is more likely to accurately stage the melanoma if it is in situ or superficially invasive than if it is more deeply invasive.</td>
<td>III-2, IV</td>
<td>[1], [2], [10]</td>
</tr>
<tr>
<td>Partial biopsy has been shown to underestimate T-stage in 7-34% of punch biopsies and 3-19% of shave biopsies and provides insufficient information for appropriate surgical planning in 18% of punch biopsies and 3-5% of shave biopsies.</td>
<td>III-2, IV</td>
<td>[1], [6], [4], [8], [7], [10]</td>
</tr>
<tr>
<td>Survival and the performance and outcomes of sentinel node biopsy show no differences according to partial versus complete excisional biopsy type.</td>
<td>III-2, IV</td>
<td>[11], [5], [12], [13], [7]</td>
</tr>
</tbody>
</table>
### 2.6.3.1 Recommendations

<table>
<thead>
<tr>
<th>Evidence-based recommendation</th>
<th>Grade</th>
</tr>
</thead>
<tbody>
<tr>
<td>The optimal biopsy approach for a suspicious pigmented lesion is complete excision with a 2 mm clinical margin and upper subcutis.</td>
<td>C</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Evidence-based recommendation</th>
<th>Grade</th>
</tr>
</thead>
<tbody>
<tr>
<td>Partial biopsies may not be fully representative of the lesion and need to be interpreted with caution and in light of the clinical findings to minimise incorrect false negative diagnoses and understaging.</td>
<td>C</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Evidence-based recommendation</th>
<th>Grade</th>
</tr>
</thead>
<tbody>
<tr>
<td>In carefully selected clinical circumstances (such as large in situ lesions, large facial or acral lesions or where the suspicion of melanoma is low) and in the hands of experienced clinicians, partial incisional, punch or shave biopsies may be appropriate.</td>
<td>C</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Practice point</th>
</tr>
</thead>
<tbody>
<tr>
<td>It is advisable to discuss unexpected pathology results with the reporting pathologist.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Practice point</th>
</tr>
</thead>
<tbody>
<tr>
<td>Punch biopsy should not be utilised for the routine diagnosis of suspected melanoma because this technique is associated with high rates of histopathological incorrect false negative diagnosis. Where a punch biopsy has been used for the diagnosis of a suspected BCC or SCC, and the diagnosis has been found to be melanocytic, then consideration should be given to excision of the entire lesion.</td>
</tr>
</tbody>
</table>
Clinical practice guidelines for the diagnosis and management of melanoma

Practice point

The use of deep shave excision (saucerisation) should be limited to in situ or superficially invasive melanomas to preserve prognostic features and optimise accurate planning of therapy.

2.6.4 Conclusion

2.6.4.1 Issues requiring more clinical research

A better understanding of the role of deep shave excision (saucerisation) and superficial shave biopsy is needed.

Future studies are needed that clearly define the intention of the biopsying clinician to partially or completely biopsy each lesion. The index of clinical suspicion for each lesion would be helpful to further understand the intention of the clinician. Studies should include a clear description of the intended biopsy method to distinguish superficial shave biopsy from deep shave excision (saucerisation) and partial punch incision from punch excision. The presently available studies are retrospective and because they group attempts at partial or complete biopsy by different methods, results vary widely.

Studies that evaluate the morbidity and cosmetic outcomes associated with different biopsy types are also needed.

Back to top

2.6.5 References


Clinical practice guidelines for the diagnosis and management of melanoma


Back to top

These guidelines have been developed as web-based guidelines and the pdf serves as a reference copy only. Please note that this material was published on 16:43, 6 April 2017 and is no longer current.
2.6.6 Appendices

2.7 Clinical information for the pathologist

The search key parameter is the name of the saved search from our PubMed account. It should be a unique name which represents the guideline, topic being covered and should easily identify the clinical question it is associated with.

Appendices

Back to top
2.8 Definitive margins for excision of primary melanoma

Supported by

Contents

1 Background
2 Economic outcomes, patient preferences and adverse events
3 References
4 Appendices

2.8.1 Background

Surgery is currently the only potentially curative treatment for primary cutaneous melanoma. Standard treatment is wide local excision (WLE) of the skin and subcutaneous tissues around the melanoma with a safety margin. The aim is complete excision of all in situ and invasive melanoma components. The purpose of the excision margin of additional tissue is to remove both the primary tumour and any melanoma cells that might have spread from the primary melanoma into the surrounding skin and subcutaneous tissue. If the malignant cells have spread no further, and are entirely included in the wider excision margin, the operation should prove to be curative.

Complete excision should be confirmed by histological examination of the excised specimen with special reference to the periphery. When present, the in-situ component (which may not be apparent macroscopically), often extends beyond the invasive melanoma, and complete excision of both is mandatory.

The width of excision margins is important because there could be trade-off between a better cosmetic result and poorer long-term outcomes if margins become too narrow.

The recommendations for the width of melanoma excision margins are based on the Breslow thickness of the primary melanoma at its thickest depth of invasion, as determined by histological assessment of the initial excision biopsy. In general, wider excision is favoured for tumours with a less favourable prognosis, such as increased Breslow thickness.

Surgical excision margins according to the tumour thickness have been assessed in six randomised controlled trials (RCTs) including a total of 4233 patients. All six RCTs assess width of excision but do not consider depth of excision. These RCTs compare narrow (1 to 2 cm) versus wide (3 to 5 cm) excision margins and assess outcomes including overall survival, melanoma specific survival and ‘local recurrence’, with median follow-up ranging from 5 to 16 years. However, no RCT has yet addressed the most important question of 1cm vs 2cm surgical margins for intermediate thickness (≥ 1mm to 4mm) and thick (> 4mm) melanomas in terms of
clinical outcome (recurrence and survival) which is what is required to answer the question of whether 1cm margins are adequate and safe for treatment of all melanoma Breslow thicknesses. In addition, definitions of 'local recurrence' are often inconsistent or unstated, and the impact on patient survival is unclear, so 'local recurrence' data must be interpreted with caution. True local recurrence is development of melanoma associated with the scar. In addition, the RCTs have been further assessed in six systematic reviews and meta-analyses where a primary melanoma has been previously excised.[7][8][9][10][11][12] Re-occurrence of melanoma close to but away from the previous primary melanoma excision scar typically represents lymphatic metastasis also termed "local satellitosis". These different situations have been often combined inappropriately as "local recurrence". There are also several published case series addressing excision margins that provide further data. Unfortunately, the extent of surgical excision margins that should be used for a given thickness of melanoma and the magnitude of benefit of different margins remains unclear because the trials use different criteria other than 1 vs 2 cm margins to directly compare invasive melanomas.

There are no RCTs which assess depth of excision. Recent studies suggest that excision of the deep fascia does not improve the outcome of melanomas thicker than 1 mm[13] or 2 mm[14] but results of these retrospective studies must be interpreted with caution because accurate data collection is often difficult. The depth of excision in usual clinical practice is excision down to but not including the deep fascia, unless the fascia is involved with tumour or is technically warranted.

However, in case of thick lesions, in the absence of a sufficient subcutis layer and in special areas where the deep fascia is less clearly defined, such as the face, neck and breast, the vertical excision margins require adaptation to the anatomic condition, for example down to the perichondrium on the ear. Similarly, for body sites where there is particularly deep subcutis, it is usual practice to excise to a depth equal to the recommended lateral (radial) excision margins for that specific melanoma; in these cases it is not deemed necessary to excise right down to fascia.

Acral lentiginous and subungual melanomas are specific types of cutaneous melanoma that arise in the extremities/soles/palms and nail matrix respectively. Treatment of these melanomas for the most part has not been assessed in trials to assist in decision making. Case series data offers the best quality data currently to help guide treatment approaches.

Back to top

2.8.2 Economic outcomes, patient preferences and adverse events

The available RCTs, systematic reviews and meta-analyses do not assess economic outcomes and patient preferences regarding width of excision. The Cochrane review does however state, “From the individual’s point of view, when faced with a diagnosis of melanoma, the most important consideration is to make sure that it is removed with as much certainty as possible so that it is all gone! The size and depth of the excision should therefore err on the side of safety first. However, quality of life after surgery is an important consideration and unnecessary disfigurement should be avoided.” An optimal safe balance is therefore is desirable to achieve survival and quality of life.

However, three trials, the Intergroup,[1] the UKMSG[6] and the 1992 Swedish Study,[4] do report adverse event outcome measures.[insert citations here]
The Intergroup trial[^1] assessed skin grafting, hospital stay, wound infection rate, wound dehiscence (skin separation) rates:

- The rate of skin grafts was reduced from 46% with 4 cm surgical margins to 11% with 2 cm surgical margins (P < 0.001).
- For the study cohort as a whole, the hospital stay was reduced from 7.0 days for participants receiving 4 cm surgical margins to 5.2 days for those receiving 2 cm margins (P = 0.0001). This reduction in length of hospital admission was mainly due to the reduced need for skin grafting, since the hospital stay for those who had a skin graft was 3.5 days longer than that for those who had a primary wound closure (6.5 days versus 3.0, P < 0.01).
- There was no significant difference between wound infection rates (4.6% and 5.4%) between the two groups (4 and 2 cm margins respectively).
- There was no significant difference between wound dehiscence rates (4.2% and 4.6%) between the two groups (4 and 2 cm margins respectively).

The UKMSG trial[^6] stated that the rate of surgical complications was 7.8% among participants with a 1 cm excision margin compared with 13.9% among those with a 3 cm excision margin (P = 0.05).

The 1992 Swedish Study[^4] summarised their rates of primary closures, graft and flap between the two groups. Primary closure of the wound was possible in 319 patients (69%) in the 2-cm group compared with 173 (37%) in the 4-cm group. Split skin graft was used in 58 patients (12%) and 223 (47%), in the narrow and wide excision groups respectively. A surgical flap was used in 19 patients (4%) in the narrow excision group and 27 (6%) in the wide excision group.

These data reflect practices at the times that the studies were conducted, using wide excision margins (4-5cm margins). With the narrower margins used in current practices (1-2cm) these outcome data, such as lengths of hospital stay, may be different.

See the following sections:

- Excision margins for melanoma in situ
- Excision margins for invasive melanomas and melanomas at other sites

2.8.3 References


Back to top

These guidelines have been developed as web-based guidelines and the pdf serves as a reference copy only. Please note that this material was published on 16:43, 6 April 2017 and is no longer current.
2.9 Melanoma in situ

As for invasive melanoma, the treatment for melanoma \textit{in situ}, including lentigo maligna (LM), is complete surgical excision with clear margins. For excision to be successful, a margin of clinically normal skin must be included because macroscopically invisible tumour often exists at the margins. Use of magnification, bright light and possibly Wood’s lighting or confocal microscopy for preoperative marking are useful methods for improving the accurate definition of detectable margins.

Back to top
### 2.9.2 Evidence

There are no RCTs and limited case series data to help direct excision of melanoma *in situ*.\(^1\) Given this lack of evidence, in 1992 consensus guidelines were published suggesting that 5 mm excision margins should be adequate for melanoma *in situ*. However, recent studies have shown that 5 mm margins might be inadequate in some situations and can lead to significant rates of disease recurrence, particularly for head and neck disease.

In many cases, in-situ melanoma margins can be accurately determined pre-operatively by careful examination and an adequate margin of ≥ 5mm can be confirmed by pathology. In some cases Mohs surgery or staged serial excision may have a role, but the accuracy is lesion dependant and operator dependant. Unfortunately Mohs surgery currently is not universally available or affordable in Australia. Most international guidelines suggest 5 mm margins for melanoma in situ.\(^2\)[3]\(^4\) The BMJ Best Practice monograph on melanoma\(^4\) states that “For melanoma in situ the recommended surgical margin is 0.5 cm. Some studies have found that this margin will be inadequate in some (up to 50% of) cases of melanoma in situ and particularly lentigo maligna. Options for dealing with this include: (a) wide excision with 1-cm margin; (b) staged excision with careful margin assessment; and (c) Mohs surgery.” The 2010 UK guidelines state 5 mm margins to achieve complete histological clearance.\(^5\) The 2011 US guidelines go further recommending 5 mm-1 cm margins and state that “wider margins may be necessary for lentigo maligna subtypes”\(^6\).

### 2.9.3 Evidence summary and recommendations

#### Evidence summary

<table>
<thead>
<tr>
<th>Evidence summary</th>
<th>Level</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>There is case series evidence suggesting that 5 mm margins are often adequate to treat melanoma <em>in situ</em>. However, in some cases of melanoma <em>in situ</em> 5mm margins are inadequate and may lead to significant rates of disease recurrence.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>IV</td>
<td>[7], [8], [9], [10], [11], [12]</td>
</tr>
</tbody>
</table>

#### 2.9.3.1 Recommendations

<table>
<thead>
<tr>
<th>Evidence-based recommendation</th>
<th>Grade</th>
</tr>
</thead>
<tbody>
<tr>
<td>After initial excision biopsy, the radial excision margins, measured clinically from the edge of the melanoma, should be 5-10 mm (measured with good lighting and magnification) with the aim of achieving complete histological clearance. Melanoma <em>in situ</em> of non-lentigo maligna type is likely to be completely excised with 5mm margins whereas lentigo maligna may require wider excision. Minimum clearances from all margins should be stated/assessed. Consideration should be given to further excision if necessary; positive histological margins are unacceptable.</td>
<td>D</td>
</tr>
</tbody>
</table>
Practice point

Excisions should have vertical edges to ensure consistent margins.

Practice point

For all melanomas, minimum clearances from all margins should be stated/assessed. When necessary, further excision should be performed in order to achieve the appropriate margin of clearance.

Practice point

Excision biopsy of the complete lesion with a narrow (2mm) margin is appropriate for definitive diagnosis of primary melanoma. Once the diagnosis of melanoma has been made, re-excision of the lesion (biopsy site) should then be performed in order to achieve the definitive, wider margins that are recommended in these guidelines.

Practice point

Depth of excision in usual clinical practice is excision down to but not including the deep fascia unless it is involved or has been reached during the diagnostic excision. For body sites where there is particularly deep subcutis, it is usual practice to excise to a depth equal to the recommended lateral (radial) excision margins for that specific melanoma; in these cases it is not deemed necessary to excise right down to fascia.

Practice point

Where tissue flexibility is limited, a flap repair or skin graft may be necessary subsequent to an adequate margin of removal.
**Practice point**

Most primary melanomas can be treated as an outpatient under local anaesthesia or as a day-case.

**Practice point**

Patients should be informed that surgical excision may be followed by wound infection, bleeding, haematoma, failure of the skin graft or flap, risk of numbness, a non-cosmetic scar, dehiscence and the possibility of further surgery.

**Practice point**

Some tumours may be incompletely excised despite using the above-recommended margins. These include melanomas occurring in severely sun-damaged skin (e.g. LM) and those with difficult-to-define margins (e.g. amelanotic and desmoplastic melanomas). In these categories, the presence of atypical melanocytes at the margins of excision should be detected by comprehensive histological examination (including immunohistochemical staining) and followed by wider excision as appropriate. Alternatively, staged serial excision (also known as ‘slow Mohs’ surgery) may be utilised to achieve complete histological clearance of melanoma in situ/lentigo maligna. Pre-operative mapping of the extent of some lesions with confocal microscopy may be useful and is available in some centres. Referral to a specialist melanoma centre or discussion in a multidisciplinary meeting should be considered for difficult or complicated cases.

**Practice point**

Amelanotic melanoma can present significant difficulties for defining a margin with up to one third of subungual and nodular melanomas being non-pigmented. This may dictate choice of a wider margin, or further re-excision, where practicable.
2.9.3.2 Supplement. Moh’s surgery and staged serial excision

A large prospective study[7] assessed complete clearance of 1120 melanomas in situ excised by Mohs micrographic surgery with frozen-section examination of the margin. Six millimetre margins were adequate for complete clearance in 86% of all tumours; 9 mm margins were adequate for complete clearance in 98.9% of all tumours. A 1.2 cm margin yielded 99.4% clearance, 1.5 cm margin yielded 99.6% clearance, and 3 cm margin yielded 100% clearance. The authors state that “the frequently recommended 5 mm margin for melanoma is inadequate. Standard surgical excision of melanoma in situ should include 9 mm of normal-appearing skin, similar to that recommended for early invasive melanoma”. This study includes a mixture of cases of melanoma in situ, both LM and non-lentigo maligna type, and it is possible that LM requires a wider margin than other melanomas in situ.

A retrospective review of 192 cases of melanoma in situ[8] found that LM required wider margins for complete excision than did non-lentigo maligna melanoma in situ.

In another retrospective study of 117 LM and lentigo maligna melanoma (LMM) cases treated with a staged margin-controlled excision technique,[9] the mean total surgical margin required for excision of LM was 7.1 mm and was 10.3 mm for LMM. Of the tumours diagnosed as LM on initial biopsy specimen, 16% were found to have unsuspected invasion. Total surgical margin was associated with initial clinical lesion diameter. The authors concluded that the standard excision margins for LM and LMM are often inadequate and occult invasive melanoma occurs in LM. Dermatoscopy and confocal microscopy may be useful in defining margins before excision of melanoma in situ.

A retrospective review of 343 cases of melanoma in situ on the head and neck treated by Mohs micrographic surgery[10] showed that 65% of cases were cleared by a 5 mm margin whilst 15 mm margins were needed to obtain a 97% clearance rate. The authors concluded that “melanoma in situ on the head and neck can spread significantly beyond the clinical margins and demonstrates the importance of confirming clearance histologically before closure procedures. Mohs surgery has the advantage of total margin evaluation and where available it may be reasonable to start with 5 mm margins. Where Mohs surgery is not a treatment option, the authors would advocate larger excision margins of ≥ 10 mm.”

In a study of 51 cases of facial LM and thin (<1 mm) LMM, with LMM present in nine lesions (average Breslow depth, 0.65 mm),[11] peripheral margin control was performed with repeated margin excision until histological clearance of the lesion. Margins required for clearance of LM and LMM averaged 1.0 and 1.3 cm, respectively. No recurrences were identified with long-term follow-up. Immediate reconstruction was performed in all cases.

In another retrospective review of 293 cases of LM and LMM treated by geometric staged excision,[12] the mean margin to clearance after excision was 6.6 mm for LM and 8.2 mm for LMM. Of concern, 26.6% of LM would not have been adequately excised using traditional 5 mm margins. The rate of recurrence of after geometric staged excision was 1.7% with a mean of 32.3 months of follow up. A total of 11.7% of LMM was initially diagnosed as LM on biopsy, with the invasive component discovered only after excision.
Zitelli comments that “Many surgeons shudder at the thought of such wide margins on the head and neck, and therefore it is important to note that Mohs surgery using MART 1 immunostains offers a way to keep more narrow margins for the majority of patients yet still have the ability to identify the outlier patients with wide subclinical extensions of MIS. The importance of clearing MIS on the first procedure is that recurrence appears as invasive melanoma of 1-mm thickness in 23% of recurrences.”\[13\]

Back to top

2.9.4 References


2.10 Invasive melanomas

There are no RCTs that specifically assess only melanomas less than 1 mm thick. However, three of the RCTs that assessed melanomas ≤ 2mm thick included 762 participants with melanomas ≤ 1mm thick. These were the French trial (159 participants),[1] 1982 Swedish trial (244 participants)[2] and the World Health Organisation (WHO) trial (359 participants).[3] No difference in mortality was found for wider excision (5 cm in the French study,[1] 5 cm in the 1982 Swedish study,[2] 3 cm in the WHO study[3]) compared with narrower excision (2 cm in the French study,[1] 2 cm in the 1982 Swedish study,[2] 1 cm in the WHO study[3]). Of note, only 185 participants (WHO trial[3]) were treated with a 1 cm excision margin.

A recently published case-control study of 11,290 patients with thin melanomas (≤ 1 mm thick) showed that local recurrence was associated with < 8 mm histologic excision margins (corresponding to < 1 cm margins in vivo), suggesting that a ≥ 1 cm clinical excision margin for thin melanomas reduces the risk of local recurrence.[4]
Therefore, there is only limited data on which to base clinical recommendations for excision margins for melanoma ≤ 1mm thick. However, a 1 cm margin is widely accepted as standard treatment for thin (< 1 mm) melanomas and most international guidelines recommend 1 cm excision margins for melanoma < 1 mm thick.

See the evidence based recommendation.

Back to top

2.10.2 Melanomas 1.01 mm–2.00 mm thick

Four RCTs assessed melanomas between 1 mm and 2 mm thick and included 1429 patients. These were the French trial (167 participants), the 1982 Swedish trial (745 participants), the WHO trial (245 participants) and the Intergroup trial (272 participants). None of these trials demonstrated a statistically significant difference in overall survival between the two groups that were treated with wide (5 cm in the French study, 5 cm in the 1982 Swedish study, 3 cm in the WHO study, 4 cm in Intergroup study) or narrow (2 cm in the French study, 2 cm in the 1982 Swedish study, 1 cm in the WHO study, 2 cm in the Intergroup study) excision. Of note, only 113 participants (WHO trial) were treated with a 1 cm excision margin.

Three retrospective studies have assessed the width of excision margins for melanomas ≤ 2 mm thick, but the magnitude of any potential associations is difficult to understand, due to the need for multivariate adjustment for confounding by other risk factors. A large single centre retrospective study of 2681 patients with melanoma ≤ 2 mm thick suggested that a 1 cm clinical margin was adequate for cutaneous melanomas ≤ 2 mm in thickness and does not impact local recurrence or survival. In another large single centre retrospective study of 2131 patients with primary cutaneous melanomas 1.01-2.00 mm thick, pathologic excision margins of < 8 mm were associated with worse regional node recurrence-free survival and distant recurrence-free survival compared with margins ≥ 8 mm (corresponding to ≥ 1 cm surgical margins), but did not translate into a statistically significant difference in melanoma-specific survival. In another retrospective single centre series of 576 patients with 1-2 mm thick melanomas, 1 cm margins were associated with a small increase in local recurrence compared with 2 cm margins but this did not impact on overall survival.

Again, there are only limited data on which to base clinical recommendations for excision margins for melanoma 1.01 mm–2.00 mm thick. There is little data to help differentiate between the clinical outcomes (local recurrence and survival) for 1 cm and 2 cm excision margins for these tumours. Most international guidelines recommend either 1 cm excision margins or 1-2 cm excision margins for 1.01 mm–2.00 mm melanoma.

See the evidence based recommendation.

Back to top
2.10.3 Melanomas 2.01 mm–4.00 mm thick

Three RCTs included participants who had melanomas between 2 and 4 mm thick and included 1516 patients. These were the Intergroup trial (190 participants),[5] the 1992 Swedish trial (666 participants)[9] and the United Kingdom Melanoma Study Group (UKMSG) trial (approximately 660 participants).[10] None of these trials demonstrated a statistically significant difference in overall survival between the two groups who were treated with wide (4 cm in the Intergroup study,[5] 4 cm in the 1992 Swedish study,[9] 3 cm in UKMSG study[10]) or narrow (2 cm in the Intergroup study,[5] 2 cm in the 1992 Swedish study,[9] 1 cm in UKMSG study[10]) excision.

The UKMSG trial "found a greater risk of locoregional recurrence when melanomas that were at least 2 mm thick were excised with a 1-cm margin, rather than a 3-cm margin (hazard ratio 1.26; 95 percent confidence interval, 1.00 to 1.59; P=0.05)". However, it should be noted that this combined outcome measure of locoregional recurrence was defined only after the trial had been commenced (that is, locoregional recurrence was not predefined in the study protocol).

The recently updated UKMSG trial showed a statistically significant improvement in melanoma specific survival (MSS) in favour of wide excision compared with narrow excision (HR 1.24: 95% CI 1.01 – 1.53; p = 0.041) but no statistically significant difference in overall survival between the 2 groups (hazard ratio [HR] 1.14, 95% CI 0.96 – 1.36; p = 0.14).[10] It is difficult to interpret the implications of this modest improvement in melanoma specific survival in the absence of any significant difference in overall survival. Of note, melanoma specific survival and overall survival were both secondary outcomes in this study. Melanoma specific survival is more difficult than overall survival to measure accurately because it relies on accurate information about cause of death. A significant number of melanomas in the UKMSG study were thick melanomas over 4 mm, which may have influenced the overall study results. In an accompanying editorial, it is suggested that “the excess nodal disease in the narrow margin group was indicative of poor prognostic disease before the intervention, rather than resulting from the narrow margin intervention itself” which might be an explanation of the significant difference in locoregional recurrence. It should also be noted that sentinel node biopsy was not used in the UKMSG trial and it is not known how this might have altered locoregional recurrence and the survival outcome in that study.

In a large single centre retrospective review of 1587 patients with melanomas 2.01 mm–4.00 mm thick, a histopathologic excision margin of 8 mm or more (roughly equivalent to a ≥ 1 cm surgical margin) was associated with increased local and intransit recurrence-free survival and disease-free survival compared with a less than 8 mm margin.[11] Another retrospective single centre cohort study of 325 patients with melanoma > 2 mm thick evaluating 1 cm or 2 cm excision margins showed no significant differences in locoregional and distant metastasis, and disease-free and overall survival between the groups.[12]

Given there is no difference in overall survival when comparing 4 cm and 2 cm margins in the Intergroup study[5] and 1992 Swedish study,[9] it seems reasonable to conclude that in most cases there is no need to take more than 2 cm margins for thick melanomas. Indeed, there is no convincing RCT evidence that a margin greater than 2 cm offers additional benefit for the patient in terms of overall survival or ‘local recurrence’, irrespective
of melanoma thickness. The clinical significance of the modest improvement in melanoma specific survival in the UKMSG trial\[10\] in the 3 cm excision group compared with the 1 cm excision group in the absence of benefit in overall survival remains unclear. On balance, given the available evidence, we continue to recommend 1-2 cm excision margins for melanomas of Breslow thickness 2-4 mm until more robust data is available. This is unchanged from our 2008 recommendation. However, we recognise that in certain areas of the body (eg face) and in the frail, excision margins greater than 1cm may not be possible.

See the evidence based recommendations

Back to top

2.10.4 Melanomas > 4 mm thick

Approximately 240 participants in the UKMSG study had melanomas > 4 mm thick.\[10\] A further 270 participants in the 1992 Swedish Study had melanomas 4 mm or thicker.\[9\] In both of these studies there was no statistically significant difference in overall survival between the two groups who were treated with wide or narrow excision.\[10][9\] Within these two studies patients with melanomas > 4 mm were analysed as part of the entire cohort and not as separate groups so it is not known how well the overall results can be extrapolated to these thicker melanomas.\[10][9\]

In a retrospective study of 632 clinically lymph node negative patients with melanomas more than 4 mm thick, histopathologically determined primary tumour excision margins more than 16 mm (corresponding to 2 cm surgical margins) were associated with better local control compared with narrower margins.\[13\]

No RCT data exist to show that any margin wider than 2 cm (that is 3, 4, or 5 cm) would result in any superior disease-specific outcomes, but these wider margins are associated with increased surgical morbidity. Most international guidelines suggest an excision margin of 2 cm for thick tumours over 4 mm thick. Individual adverse prognostic melanoma characteristics may dictate more caution and wider excision margins as clinically appropriate, although RCT data is lacking.

See the evidence based recommendations

Back to top

2.10.5 Melanomas at other sites

The six RCTs\[5][3][2][9][1][10\] included in our review do not adequately address the issues of melanomas in specific body sites, such as head and neck, distal extremities, hands and feet (including digits and subungual melanomas). For example, only the French study included melanomas on the head and neck and this involved only 16 participants.\[1\]

In special areas where the deep fascia is less clearly defined, such as the face, neck and breast, the vertical excision margins require adaptation to the anatomic condition, for example down to the perichondrium on the ear.
The morbidity (particularly 'cost' for reconstruction, complications or potential disfigurement) associated with wider excisions on the face is likely to be greater than for those on the trunk. For example, even 1 cm margins are potentially problematic in critical facial locations. A few non-randomised trials suggest that excision margins on the head and neck can be safely reduced but the results must be interpreted with caution given the nature of the studies. There are no RCT data that demonstrate whether narrower excision margins impact on mortality or recurrence rates in head and neck melanoma.

In a recently published study, 79 cases of primary, invasive head and neck melanoma were treated by wide local excision and followed prospectively for local recurrence.\textsuperscript{[14]} Forty-two wide local excisions were performed according to current National Comprehensive Cancer Network (NCCN) practice guidelines and reduced margins were utilized in 37 cases to preserve critical anatomical structures such as the eyelid, nose, mouth and auricle. Reducing margins of wide local excision did not increase local recurrence rates as demonstrated by local recurrence-free survival (90.4\% vs. 91.9\%, \( P = 0.806 \)) at 5 years follow-up, suggesting that excision margins may be safely reduced in melanomas in close proximity to structures of the head and neck, but this was a small non-randomised study.

In a retrospective study of 368 melanomas of the face, the authors suggest that reduced excision margins can be employed in melanomas of the face.\textsuperscript{[15]}

A prospective study evaluated 161 patients with melanoma of the external ear. The median thickness of the tumours in the present study was 1.08 mm (mean 1.51 mm; range 0.18–8.50 mm), and the median excision margins were 11.0 mm (mean 12.61 mm; range 2.0–31.0 mm). The 3-year disease-specific survival rate was 98\%, and the 3-year recurrence-free survival rate was 83\%. The authors concluded that the use of micrographic surgery, made it possible to reduce the excision margins (median 5 mm vs. 10 mm) without an increased risk of recurrence.\textsuperscript{[16]}

A retrospective chart review of 78 patients evaluated the prognostic variables and clinical ramifications of melanoma of the ear.\textsuperscript{[17]} Melanoma thickness averaged 1.7 mm (range 0.2–7.0 mm). After a mean follow-up of 55.7 months, 10 patients (13\%) had local recurrence, 9 patients (12\%) had regional recurrence, and systemic metastases had developed in 17 patients (22\%). The authors concluded that treatment of malignant melanoma of the external ear should follow current standard guidelines, which require wide local excision with negative margins.

Guidelines for wide excision of cutaneous melanomas according to Breslow thickness are impractical when considering melanomas arising on eyelid skin. A retrospective study of 56 patients with invasive cutaneous eyelid melanoma sought to determine whether excision margins influenced locoregional recurrence, and to identify prognostic factors for survival in these patients.\textsuperscript{[18]} Local recurrence occurred in 12 patients (21\%), nodal metastasis in 6 (11\%) and distant metastasis in 2 (4\%). Pathological margins > 2 mm from the in situ component of the tumour were associated with increased disease-free survival (\( P = 0.029 \)) compared with margins ≤2 mm but there was no statistically significant benefit for a pathological margin > 2 mm from the...
invasive component. The results suggest that, as a minimum, an in vivo surgical margin of 3 mm (corresponding approximately to a 2 mm pathological margin after tissue fixation) is desirable for eyelid melanomas. The authors recommended a surgical excision margin of 3 mm for eyelid melanomas ≤ 1 mm in Breslow thickness but for melanomas > 1 mm in thickness, the current practice of aiming to achieve 5 mm margins would seem reasonable. Patients with lower eyelid melanomas warrant particularly close follow-up given their higher local recurrence rate.

Management of digital melanomas including the subset of subungual melanomas often includes partial amputation.\(^{[19]}^{[20]}\) As with facial lesions, there are no RCTs available to help determine whether less aggressive surgery would be as effective. Management involves achieving a balance between adequate melanoma excision with the most appropriate margins for the site and characteristics of the melanoma, while maintaining the optimal preservation of function.

See the evidence based recommendation.

Back to top

2.10.6 Evidence summary and recommendations

<table>
<thead>
<tr>
<th>Evidence summary</th>
<th>Level</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>There is no convincing RCT evidence that a margin greater than 2cm offers</td>
<td>I, II</td>
<td>^[5] ^[3] ^[2] ^[9] ^[1] ^[10] ^[21] ^[22] ^[23] ^[24] ^[25] ^[26]</td>
</tr>
<tr>
<td>additional benefit for the patient in terms of overall survival or ‘local</td>
<td></td>
<td></td>
</tr>
<tr>
<td>recurrence’, irrespective of melanoma thickness.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Furthermore, two RCTs show evidence that a margin greater than 1cm offers</td>
<td>II</td>
<td>^[3] ^[27]</td>
</tr>
<tr>
<td>no survival advantage, although it is not clear whether a wider margin reduces</td>
<td></td>
<td></td>
</tr>
<tr>
<td>the risk of ‘local recurrence’.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Systematic review indicates that there are currently inadequate data to confirm</td>
<td>I</td>
<td>^[21] ^[22] ^[23] ^[24] ^[25] ^[26]</td>
</tr>
<tr>
<td>a mortality difference between wider and narrower excision for primary invasive</td>
<td></td>
<td></td>
</tr>
<tr>
<td>melanoma.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>For acral lentiginous and subungual melanomas there are no RCTs or systematic</td>
<td>III-2</td>
<td>^[14] ^[15] ^[17] ^[18] ^[19] ^[20]</td>
</tr>
<tr>
<td>reviews to define excision margins. Data are from retrospective case studies.</td>
<td>IV</td>
<td></td>
</tr>
<tr>
<td>There is limited RCT data for head and neck melanoma with the majority of data</td>
<td></td>
<td></td>
</tr>
<tr>
<td>also derived from retrospective case series.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Excision margins might be modified to accommodate individual anatomic sites or</td>
<td></td>
<td></td>
</tr>
<tr>
<td>functional considerations, but this practice would be based solely on case-series</td>
<td></td>
<td></td>
</tr>
<tr>
<td>information, and individual factors, rather than RCT evidence which is currently</td>
<td></td>
<td></td>
</tr>
<tr>
<td>lacking.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Clinical practice guidelines for the diagnosis and management of melanoma

2.10.6.1 Recommendations

<table>
<thead>
<tr>
<th>Evidence-based recommendation</th>
<th>Grade</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>(pT1) melanoma &lt; 1.0 mm</strong></td>
<td>B</td>
</tr>
<tr>
<td>After initial excision biopsy, the radial excision margins, measured clinically from the edge of the melanoma, should be 1 cm. Minimum clearances from all margins should be stated/assessed. Consideration should be given to further excision if necessary; positive histological margins are unacceptable.</td>
<td></td>
</tr>
</tbody>
</table>

Back to top

<table>
<thead>
<tr>
<th>Evidence-based recommendation</th>
<th>Grade</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>(pT2) melanoma 1.01 mm–2.00 mm</strong></td>
<td>B</td>
</tr>
<tr>
<td>After initial excision biopsy, the radial excision margins, measured clinically from the edge of the melanoma, should be 1–2 cm. Minimum clearances from all margins should be stated/assessed. Consideration should be given to further excision if necessary; positive histological margins are unacceptable.</td>
<td></td>
</tr>
</tbody>
</table>

Back to top

<table>
<thead>
<tr>
<th>Evidence-based recommendation</th>
<th>Grade</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>(pT3) melanoma 2.01 mm–4.00 mm</strong></td>
<td>B</td>
</tr>
</tbody>
</table>
| After initial excision biopsy, the radial excision margins, measured clinically from the edge of the melanoma, should be 1–2 cm. Minimum clearances from all margins should be stated/assessed. Consideration should be given to further excision if necessary; positive histological margins are unacceptable.  

Caution should be exercised for melanomas 2.01–4.00 mm thick, especially with adverse prognostic factors, because evidence concerning optimal excision margins is unclear. Where possible, it may be desirable to take a wider margin (2 cm) for these tumours depending on the tumour site and characteristics, and prevailing surgeon/patient preferences. |

Back to top
### Evidence-based recommendation

**(pT4) melanoma > 4.0 mm**

After initial excision biopsy, the radial excision margins, measured clinically from the edge of the melanoma, should be 2 cm. Minimum clearances from all margins should be stated/assessed. Consideration should be given to further excision if necessary; positive histological margins are unacceptable.

<table>
<thead>
<tr>
<th>Grade</th>
</tr>
</thead>
<tbody>
<tr>
<td>B</td>
</tr>
</tbody>
</table>

---

### Evidence-based recommendation

Acral lentiginous and subungual melanoma are usually treated with a minimum margin as set out above, where practicable, including partial digital amputation usually incorporating the joint immediately proximal to the melanoma.

<table>
<thead>
<tr>
<th>Grade</th>
</tr>
</thead>
<tbody>
<tr>
<td>D</td>
</tr>
</tbody>
</table>

---

### Evidence-based recommendation

Excision margins might be modified to accommodate individual anatomic sites or functional considerations, but this practice would be based solely on case-series information, and individual factors, rather than RCT evidence which is currently lacking.

<table>
<thead>
<tr>
<th>Grade</th>
</tr>
</thead>
<tbody>
<tr>
<td>D</td>
</tr>
</tbody>
</table>

---

### Practice point

Excisions should have vertical edges to ensure consistent margins.

---

### Practice point

For all melanomas, minimum clearances from all margins should be stated/assessed. Consideration should be given to further excision if necessary because positive histological margins are unacceptable.
Practice point

Excision biopsy of the complete lesion with a narrow (2mm) margin is appropriate for the definitive diagnosis of primary melanoma. Once the diagnosis of melanoma has been made, re-excision of the lesion (biopsy site) should then be performed in order to achieve the definitive, wider margins that are recommended in these guidelines.

Practice point

Depth of excision in usual clinical practice is excision down to but not including the deep fascia unless it is involved or has been reached during the diagnostic excision. For body sites where there is particularly deep subcutis, it is usual practice to excise to a depth equal to the recommended lateral (radial) excision margins for that specific melanoma; in these cases it is not deemed necessary to excise right down to fascia.

Practice point

Where tissue flexibility is limited, a flap repair or skin graft is often necessary subsequent to an adequate margin of removal.

Practice point

Most primary melanomas can be treated as an outpatient under local anaesthesia or as a day-case.
**Practice point**

Patients should be informed that surgical excision may be followed by wound infection, bleeding, haematoma, failure of the skin graft or flap, risk of numbness, a non-cosmetic scar, dehiscence and the possibility of further surgery.

**Practice point**

Some tumours may be incompletely excised despite using the above-recommended margins. These include melanomas occurring in severely sun-damaged skin (e.g. lentigo maligna) and those with difficult-to-define margins (e.g. amelanotic and desmoplastic melanomas). In these categories, the presence of atypical melanocytes at the margins of excision should be detected by comprehensive histological examination (including immunohistochemical staining) and followed by wider excision.

**Practice point**

Amelanotic melanoma can present significant difficulties for defining a margin with up to one third of subungual and nodular melanomas being non-pigmented. This may dictate choice of a wider margin, or further re-excision, where practicable.

**Practice point**

For patients with deeper invasive melanomas (> 1 mm thick), referral to a specialised melanoma centre or discussion in a multidisciplinary meeting should be considered to ensure that best practice is implemented and for the collection of national outcome data. This may present logistic difficulties in regional and remote areas, but input from a specialist melanoma centre.
Clinical practice guidelines for the diagnosis and management of melanoma

2.10.7 References

1. ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 1.8 Khayat D, Rixe O, Martin G, Soubrane C, Banzet M, et al. Surgical margins in cutaneous melanoma (2 cm versus 5 cm for lesions measuring less than 2.1-mm thick). Cancer 2003 Apr 15;97(8):1941-6 Available from: http://www.ncbi.nlm.nih.gov/pubmed/12673721.


5. ↑ 5.0 5.1 5.2 5.3 5.4 5.5 5.6 5.7 5.8 Balch CM, Soong SJ, Smith T,Ross MI, Urist MM, et al. Long-term results of a prospective surgical trial comparing 2 cm vs. 4 cm excision margins for 740 patients with 1-4 mm melanomas. Ann Surg Oncol 2001 Mar 1;8(2):101-8 Available from: http://www.ncbi.nlm.nih.gov/pubmed/11258773.


2.10.8 Appendices

2.11 Sentinel node biopsy

Supported by
2.11.1 Background

Sentinel lymph node biopsy (SLNB) is a surgical technique to identify low volume metastatic disease within the draining lymph node basin in patients undergoing treatment for primary melanoma. The technique was developed to identify patients with a positive draining nodal basin and thereby minimise the morbidity associated with elective lymph node dissection in patients who may not require this procedure. Numerous studies have consistently demonstrated that the status of the sentinel lymph node (SLN) reflects the status of the entire draining nodal basin as measured by elective lymph node dissection.\(^1\)

The technique of SLNB has been extensively described. Briefly, it involves pre-operative lymphoscintigraphy to identify the draining nodal basin for the anatomical location of the primary melanoma. This is followed by intraoperative intradermal injection of the melanoma site with patent blue dye. Intraoperative exploration through a small incision allows the identification of SLNs. A node is considered a SLN if it has tracer uptake and/or is stained blue. This dual modality approach allows the successful identification of a SLN in over 95% of patients.

Back to top

2.11.2 Summary of systematic review results

There have been numerous large studies published since the last guidelines regarding the role of SLNB in melanoma. The most important of these publications is the final report of the Multicentre Selective Lymphadenectomy Trial (MSLT-I).\(^2\) This was a phase III randomised controlled trial comparing wide excision of the primary melanoma and regional nodal observation with wide excision and SLNB followed by immediate completion lymph node dissection (cLND) for patients with a positive SLNB. Patients in the observation arm underwent therapeutic lymph node dissection (tLND) if they developed clinical lymph node involvement. The study included 1661 patients and the main study population was the 1347 with melanoma of Breslow thickness between 1.2 and 3.5 mm. The rate of SLN involvement in the SLNB arm was 16% and of those patients with a negative results, the rate of subsequent nodal relapse (false negative SLNB) was 4.8%\(^2\).

The reported primary endpoint of the study\(^2\) was melanoma specific survival (MSS) and the final report demonstrated no difference in MSS for patients with intermediate thickness melanoma between those in the SLNB group (10 year MSS =81.4%) compared with the observation group (10 year MSS = 78.3%) (HR for
death=0.84; 95% CI 0.64-1.09; P=0.18). Furthermore, there was no difference in distant disease-free survival between the two groups (HR=0.89; 95% CI 0.70-1.13; P=0.34). A post-hoc latent subgroup analysis was developed in an attempt to estimate treatment effect for the subgroup of patients who were SLN positive (ie. at baseline in the biopsy arm and those who would have tested positive had SLNB been performed in the observation arm). This showed that patients with intermediate thickness melanoma and nodal metastasis had a 10-year MSS of 62.1% with lymphadenectomy compared to 41.5% with observation (HR for death=0.56; 95% CI 0.37-0.84; P=0.006).

Controversy lies in the validity of comparing two possibly biologically different groups. It is impossible to prove that all patients with micrometastases in the sentinel node would progress to clinically overt disease if left untreated. SLNB was positive in 16% of patients in the SLN arm and the estimated cumulative incidence of nodal metastases at 10 years was 21.9% (adding patients with a false negative test) compared to an estimated cumulative incidence of nodal metastasis in the observation arm of 19.5% (ratio 1.12). This suggests a 12% greater rate of nodal metastases in the SLN arm relative to the observation arm which could be explained by over diagnosis of single cell deposits in the sentinel node which may never progress (false positive SLNB), or by late nodal recurrences still pending in the observation group, or this difference may simply be attributable to chance.¹

In a multivariate analysis, the MSLT-I study showed that the status of the SLN was the strongest predictor of MSS (10 year MSS for SLN positive = 62.1% versus 85.1% for SLN negative [HR for death = 3.09; 95% CI 2.12-4.49; P<0.001]). Multiple retrospective cohort studies have confirmed on multivariate analysis that the status of the sentinel node is significantly associated with MSS and in all but one³ the status of the SLN was the most significant predictor of MSS (HR 1.5-6.9).⁴⁵⁶⁷

Many studies have described predictors of a positive SLN, the most consistent of these include tumour thickness, ulceration, primary location outside of HN, mitotic rate >0, decreasing age, nodular subtype and TIL grade.⁷⁸ Predictors of sentinel node involvement from 7,756 patients in the AJCC database are shown in Table 1.

### Table 1. Statistically significant predictors of sentinel node involvement and associated rates of involvement (total 7756 patients from Balch et al.)

<table>
<thead>
<tr>
<th>Variable</th>
<th>% patients with SLN involvement</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age</strong></td>
<td></td>
</tr>
<tr>
<td>&lt;40 years</td>
<td>21.3</td>
</tr>
<tr>
<td>40-59 years</td>
<td>20.0</td>
</tr>
<tr>
<td>≥60 years</td>
<td>17.6</td>
</tr>
<tr>
<td><strong>Gender</strong></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>20.7</td>
</tr>
<tr>
<td>Female</td>
<td>17.7</td>
</tr>
<tr>
<td><strong>Location</strong></td>
<td></td>
</tr>
<tr>
<td>Head/neck</td>
<td>15.5</td>
</tr>
</tbody>
</table>
Clinical practice guidelines for the diagnosis and management of melanoma

<table>
<thead>
<tr>
<th>Location</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Upper extremity</td>
<td>15.1</td>
</tr>
<tr>
<td>Trunk</td>
<td>21.3</td>
</tr>
<tr>
<td>Lower extremity</td>
<td>22.3</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Tumour thickness</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>≤ 1.0</td>
<td>6.0</td>
</tr>
<tr>
<td>1.01-2.0</td>
<td>14.0</td>
</tr>
<tr>
<td>2.01-4.0</td>
<td>27.3</td>
</tr>
<tr>
<td>&gt;4.0</td>
<td>39.1</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Ulceration</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Absent</td>
<td>15.6</td>
</tr>
<tr>
<td>Present</td>
<td>29.9</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Clark Level</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>I/II</td>
<td>4.5</td>
</tr>
<tr>
<td>III</td>
<td>11.9</td>
</tr>
<tr>
<td>IV</td>
<td>21.5</td>
</tr>
<tr>
<td>V</td>
<td>33.9</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Lymphovascular Invasion</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Absent</td>
<td>17.3</td>
</tr>
<tr>
<td>Present</td>
<td>47.2</td>
</tr>
</tbody>
</table>

Source: Balch et al 2014[9]

SLNB is a surgical procedure which usually requires a general anaesthetic. Complication rates for SLNB vary from 5.9-13.8%[10][11] and are significantly lower than for completion or therapeutic lymphadenectomy. Complications predominantly consist of seroma and wound infections; these are usually mild, manageable and of limited duration. Complication rates are inversely correlated with procedure volume.[11]

The addition of SLNB to the management of patients with primary melanoma involves the upfront use of increased resources, which raises the question of additional cost. Morton et al performed a cost-effectiveness analysis incorporating direct Australian health care data with the outcome data from the MSLT-1 study[12]. This study found only a slight increase in cost ($24,045 compared with $23,182 per patient) but an increase in cost effectiveness given the improved disease free survival and the reduced morbidity of completion lymph node dissection compared to therapeutic lymph node dissection for patients with macroscopic nodal disease.
2.11.2.2 Special situations

2.11.2.2.1 Thin melanoma

In thin melanomas (Breslow thickness <1 mm), the risk of a positive sentinel lymph node is low (<5%), however there are certain subgroups of patients at increased risk of nodal involvement. Predictors of a rate of SLN involvement of greater than 5% in melanoma less than 1 mm include Breslow thickness >0.75 mm combined with another high risk feature, such as ulceration, mitotic rate >1, Clark level IV or V or lymphovascular invasion. As described for intermediate thickness melanoma, in patients with thin melanoma, SLN involvement is associated with significantly worse MSS.[13]

2.11.2.2.2 Thick melanoma

The risk of SLN involvement increases with Breslow thickness. The MSLT-1 study demonstrated a SLN positive rate of 33% in patients with thick melanoma. Whilst the status of the SLN remains the most significant predictor of outcome for patients with thick melanoma (HR 2.3), the procedure itself does not offer a survival benefit in this group.[16]

2.11.2.2.3 Desmoplastic melanoma

A positive SLN is found in 13.7% of patients with desmoplastic melanoma.[17] The rate of nodal involvement differs according to whether the melanoma is a pure or mixed DM, with much lower rates in pure DM.

2.11.2.2.4 Atypical spitz naevi and spitzoid melanoma

Atypical spitz naevi are more commonly seen in younger patients, SLNB can be positive in these patients however this does not reflect malignancy nor is it a predictor of outcome, therefore SLNB is not recommended. By contrast, spitzoid melanoma is a subtype of melanoma and therefore these guidelines apply.

2.11.2.2.5 SLN after prior wide excision

Wide local excision can interrupt lymphatic drainage patterns and therefore reduce the accuracy of SLNB. A number of studies have however demonstrated the feasibility of SLNB in patients with prior WLE. Where possible SLNB should be performed at the same time as WLE.

2.11.2.2.6 Head and neck melanoma

There is increased complexity associated with SLNB in the head and neck region compared to other sites because of the anatomical proximity of the primary site to the sentinel node in addition to more complex lymphatic drainage patterns in the head and neck. As such, SLNB in the head and neck is associated with a higher false negative rate.
2.11.3 Evidence summary and recommendations

<table>
<thead>
<tr>
<th>Evidence summary</th>
<th>Level</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>The status of the sentinel lymph node is the most significant predictor of melanoma-specific survival for patients with melanoma &gt;1 mm Breslow thickness.</td>
<td>III-3, IV</td>
<td>[4], [5], [6], [7], [16]</td>
</tr>
<tr>
<td>Overall, for patients with melanoma &gt;1 mm thick, sentinel lymph node biopsy followed by immediate completion lymph node dissection for a positive node does not prolong melanoma specific survival or overall survival compared with not performing sentinel node biopsy (nodal observation) and delayed lymph node dissection for clinically detected nodes.</td>
<td>II</td>
<td>[2]</td>
</tr>
<tr>
<td>For patients with intermediate thickness melanoma (1.2-3.5mm thick) who harbour metastatic disease within the sentinel node, early intervention with sentinel lymph node biopsy may be associated with an increased melanoma specific survival compared with nodal observation.</td>
<td>III-2</td>
<td>[2]</td>
</tr>
<tr>
<td>Complication rates for sentinel lymph node biopsy are low. The procedure should be performed in a centre with appropriate expertise as complication rates are inversely related to procedure volume - this particularly applies to primaries arising in the head and neck.</td>
<td>III-3</td>
<td>[10], [11]</td>
</tr>
</tbody>
</table>

Back to top

2.11.3.1 Recommendations

<table>
<thead>
<tr>
<th>Evidence-based recommendation</th>
<th>Grade</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sentinel lymph node biopsy should be considered for all patients with melanoma greater than 1 mm in thickness and for patients with melanoma greater than 0.75 mm with other high risk pathological features to provide optimal staging and prognostic information and to maximise management options for patients who are node positive.</td>
<td>B</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Practice point</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Sentinel lymph node biopsy (SLNB) should be performed at the time of the primary wide excision.</td>
<td></td>
</tr>
</tbody>
</table>
Practice point

Sentinel lymph node biopsy (SLNB) should be performed in a centre with expertise in the procedure, including nuclear medicine, surgery and pathology to optimise the accuracy of the test.

Practice point

Patients being considered for sentinel lymph node biopsy (SLNB) should be given an opportunity to fully discuss the risks and benefits with a clinician who performs this procedure.

Practice point

A consideration of sentinel lymph node biopsy (SLNB) forms an important part of the multidisciplinary management of patients with clinically node negative cutaneous melanoma.

2.11.3.2 Conclusions

Sentinel lymph node biopsy is primarily a staging procedure which provides the best means for prognostic stratification for patients with melanoma greater than 1 mm thick and for some patients with thin melanoma with high risk features. Currently clinical trials are investigating the role of adjuvant therapy for patients with stage III melanoma (including patients identified as high risk through SLNB). The overall survival benefit of adjuvant therapies for patients with microscopic or macroscopic node positive disease is unknown at this stage however there a number of ongoing studies that will be reported in the near term.

2.11.4 Footnote

A Cochrane review has been performed regarding the use of SLNB for melanoma (Kyrgidis et al). This review has not been cited in the evidence as the NHMRC recommendations for developers of guidelines suggest that a “systematic review should consist of at least two studies” (p. 16). The paper by Kyrgidis et al only cites a single study, the MSLT-1 study, which is extensively discussed in the guidelines.
Clinical practice guidelines for the diagnosis and management of melanoma

2.11.5 References


These guidelines have been developed as web-based guidelines and the pdf serves as a reference copy only. Please note that this material was published on 16:43, 6 April 2017 and is no longer current.


2.11.6 Appendices
2.12 Complete node dissection

2.12.1 Background

In the past most patients with lymph node involvement presented with clinically apparent disease, for which therapeutic lymph node dissection (TLND) was and remains the standard of care. Other patients at moderate and high risk for lymph node involvement previously would undergo elective lymph node dissection (ELND) as a standard of care in some melanoma centres. Since the introduction of sentinel lymph node biopsy (SLNB) ELND is no longer performed. Now up to half the patients identified as having metastatic nodal disease are being diagnosed with microscopic disease by SLNB, especially in melanoma centres. Overall around 16% of patients with intermediate thickness and 33% with thick melanoma have a positive SLNB\(^1\).

Consistent with the intervention arm of the Multicenter Selective Lymphadenectomy Trial (MSLT-1), patients with a positive SLNB have been offered completion lymph node dissection (CLND) as standard of care. However, from as early as 2004 the question of whether this is necessary was addressed by the development and recruitment to the MSLT2 and from 2006 by the DeCOG-SLT study\(^2\). When CLND is done for positive SLNB the incidence of further disease in the non-sentinel lymph nodes (non-SLNs) is about 20% but, depending on the circumstances, ranges from 3% to around 66.7% when standard techniques for assessing lymphadenectomy specimens with standard histology and immunohistochemistry are used\(^3\). The risk of having positive non-SLNs varies depending on the features of the primary tumour as well as the burden and distribution of disease in the positive sentinel lymph node(s)\(^3\)[4]\(^5\). The presence of non-SLN involvement is associated with a poor prognosis\(^3\). As non-SLN positivity is a significant predictor of systemic failure, it is possible that after positive SLNB there may be no benefit to the early removal of non-SLN compared to waiting until regional relapse occurs. There is likely to be little to no benefit for the majority of patients who have CLND when there is no further nodal disease
in the regional lymph node (RLN) basin unless the sentinel node had extra-nodal spread that was not adequately cleared. In addition, CLND is often associated with significant morbidity that can compromise quality of life (QOL) indefinitely. Complications of RLN dissection may include wound complications, cosmetic and sensory neural disruption e.g. the facial nerve may be affected in a parotidectomy, fibrosis and tightness, limitations in range of movement and lymphoedema, which is more common for lower than the upper limbs.\(^6\). The DeCOG-SLT study recently reported equivalent median 3-year melanoma distant metastasis-free and overall survival for patients with positive sentinel nodes who were observed compared with those who had a CLND. Although this is supportive of avoiding CLND, the interpretation and application of these results should take into account a number of factors including not meeting the recruitment target, lower than predicted event rate, enrolling only recruiting 39% of the patient population who were eligible, that around two thirds of the patients had SLN deposits ≤ 1mm, the exclusion of head and neck primary melanoma, and that around 60% of patients received adjuvant interferon.\(^2\). It is likely that the MSLT 2 will not be mature to allow reporting of results for some years. The issue of selection bias may be relevant to both trials. There is evidence from a survey of international melanoma surgeons that there was also significant selection bias in MSLT2, with some centres that were involved in MSLT1 declining participation due to their lack of equipoise with the study question.\(^7\). Therefore the results of these pivotal clinical trials will need to be interpreted with these issues in mind.

Thus the role of CLND for all patients with a positive SLN still remains an open question. Present Australian and New Zealand guidelines and other guidelines around the world state that CLND is the standard of care for patients with a positive sentinel lymph node with the NCCN Guidelines in the US suggesting that the role of CLND should be discussed and considered.\(^8\).

Back to top

### 2.12.2 Summary of systematic review results

#### 2.12.2.1 Cancer Control

CLND after a positive SLNB has high rates of regional control and is the standard of care.\(^1\) Currently there is only immature randomised controlled trial data to indicate the safety of not doing a CLND after a positive SLNB. The DeCOG-SLT is supportive of observation as a strategy but the published data is immature and despite liberal eligibility criteria selection bias lead to the great majority of patients only having low volume sentinel node disease (≤1mm in 68-75% of cases)\(^2\). In addition to the good regional control, the best available evidence in support of the current recommendation for CLND is also the MSLT1, which found that patients who had a positive SLNB and CLND had 20% improved 10 years melanoma specific survival compared to patients who didn’t have SLNB but later relapsed in the regional lymph node field and then had TLND.\(^1\) However, these comparator groups were not randomised and these data do not differentiate whether SLNB alone is sufficient to gain that benefit, hence the need for the results from the MSLT2 and mature DeCOG-SLT data.

Other retrospective data support the MSLT1 results and may suggest a role for immediate CLND over the delayed CLND strategy, but these comparisons are biased as the delayed CLND patients all had residual disease in the regional field whereas most (70-80%) of the immediate CLND patients had no residual regional disease.\(^9\)\(^10\).
A number of retrospective studies, some analysing a prospective data base (including multiple updates of the same base patient cohort), suggest there is safety in the close observation after positive SLNB strategy\(^{[11]}\)\(^{[12]}\)\(^{[13]}\)\(^{[14]}\)\(^{[15]}\)\(^{[16]}\). These studies demonstrate acceptably low rates of regional failure and no apparent impact on MSS or OS and suggest that surgeons can identify patients who can safely avoid CLND\(^{[11]}\)\(^{[12]}\)\(^{[13]}\)\(^{[14]}\)\(^{[15]}\)\(^{[16]}\). For patients not undergoing CLND, a standardised surveillance protocol, with regular ultrasound of the nodal basin is recommended although there is no significant level of evidence to support ultrasound improving local control or overall survival.

### 2.12.2.2 Morbidity and QOL

Morbidity varies depending on the lymph node region where the CLND is done. Generally speaking, the morbidity of neck and axillary dissection is less than that of groin CLND. Immediate CLND is less morbid than TLND\(^{[16]}\)\(^{[17]}\). DeCOG-SLT reported grade 3 or 4 adverse events occurred in 14% of CLND patients.

There are no good data assessing the quality of life implications of avoiding CLND compared to having CLND. Physical consequences of CLND are clear but psychosocial implications of CLND and psychosocial implication of not having CLND are undefined.

Back to top

### 2.12.3 Evidence summary and recommendations

<table>
<thead>
<tr>
<th>Evidence summary</th>
<th>Level</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>CLND offers excellent regional control for melanoma patients with positive SLNB and is the standard of care.</td>
<td>II</td>
<td>(^{[1]})(^{[2]})</td>
</tr>
<tr>
<td>Patients randomised to SLNB who had a positive SLN followed by CLND had a 20% better survival than those patients who were observed without SLNB and later relapsed and had a TLND.</td>
<td>II</td>
<td>(^{[1]})</td>
</tr>
<tr>
<td>Multiple case series and one randomised trial with incomplete accrual and immature data suggest safety with the observation strategy in selected patients.</td>
<td>II, III-2</td>
<td>(^{[2]})(^{[11]})(^{[12]})(^{[13]})</td>
</tr>
</tbody>
</table>

#### 2.12.3.1 Recommendations

<table>
<thead>
<tr>
<th>Evidence-based recommendation</th>
<th>Grade</th>
</tr>
</thead>
<tbody>
<tr>
<td>CLND offers excellent regional control for patients with positive SLNB and is the standard of care.</td>
<td>C</td>
</tr>
</tbody>
</table>
Clinical practice guidelines for the diagnosis and management of melanoma

<table>
<thead>
<tr>
<th>Evidence-based recommendation</th>
<th>Grade</th>
</tr>
</thead>
<tbody>
<tr>
<td>Multiple case series suggest comparable oncological safety for the observation strategy in selected patients but mature randomised controlled trial evidence is still lacking.</td>
<td>D</td>
</tr>
</tbody>
</table>

**Practice point**

Observation with delayed CLND if there is regional progression should be discussed with all patients with a positive SLNB. This may be particularly relevant to those patients at lowest risk of having further nodal involvement of those with competing causes of mortality. Close clinical and ultrasound surveillance is recommended if the patient chooses observation.

2.12.4 Important considerations

1. In order to meet trial eligibility for currently open randomised trials of adjuvant systemic therapy, patients are mandated to undergo CLND. This situation may need to be revised with the trial management committees of adjuvant therapy trials as more data on the safety of observation becomes available.

2. CLND is standard of care but observation is a valid option worthy of careful informed consideration in selected patients. If the 2 RCTs indicate safety of the observation strategy, then the broad acceptance of observation will require careful analysis of the mature results of DeCOG-SLT and MSLT2 to assess whether there was significant selection bias that should result in caution when applying the results to all patients.

3. Further assessment of this question may be necessary in the era of effective adjuvant therapy as the patterns of recurrence may alter.

2.12.5 Issues requiring more clinical research study

1. A risk calculator for defining the chance of non-SLN involvement would be of assistance to more accurately inform patients of the chance of residual non-SN positive nodes.

2. Therapies that improve control of the regional lymph node field but are less morbid than surgery would be desirable for those patients at higher risk of regional failure and should be investigated. These may include systemic adjuvant targeted or immune modulating therapies and other local therapies.

3. The QOL implications of CLND compared to observation with frequent patient attendance for testing.

Back to top
2.12.6 References


2.12.7 Appendices

2.13 Treatment for lentigo maligna
Appendices

2.13.1 Primary desmoplastic neurotropic melanomas

Draft intro text here.

Michael Hughes.

See:

- What is the optimal management for primary desmoplastic neurotropic melanomas?
- What is the role of sentinel node biopsy for desmoplastic neurotropic melanomas?

2.13.2 Management of primary desmoplastic and neurotropic melanomas
2.13.3 Sentinel node biopsy for desmoplastic melanoma

3 Melanoma in children
3.1 Management of MelTUMPs

PENDING :)

3.2 Sentinel node biopsy for MelTUMPs

3.3 Excision margins in MelTUMPs

3.4 Pregnancy following a diagnosis of melanoma

Intro to be inserted

See:

- Does pregnancy following diagnosis of melanoma affect prognosis?
- What is the optimal management for pregnant women with melanoma?

3.5 Management of pregnant women with melanoma

Content to be inserted.

3.5.1 References
3.5.2 Appendices

3.6 Optimal management of pregnant women with melanoma

Content to be inserted.

3.6.1 References

3.6.2 Appendices
3.7 Continuation of HRT or oral contraceptive pill

Content to be inserted.

3.7.1 References

3.7.2 Appendices

3.8 Investigations and follow-up – Introduction

3.9 Patients with stage I and stage II melanomas

Systematic review in progress.
Appendices

3.10 Patients with in-transit/regional node disease (stage III)

Systematic review in progress.

Appendices

3.11 Patients with stage IV melanoma

Systematic review in progress.

Appendices
3.12 Follow up after initial definitive treatment

Systematic review in progress.

Appendices

3.13 Ideal frequency and duration of follow-up

Contents

1 Headings to be inserted
2 References
3 Appendices

3.13.1 Headings to be inserted

Draft content to be inserted

3.13.2 References
4 Treatment of satellite and in-transit metastases
5 Treatment of macroscopic nodal metastases

5.1 Introduction

At the time of writing of this guideline, surgery remains the standard of care for patients with symptomatic or imaging detected lymph node field relapse of melanoma. In a small proportion of patients (typically <5%), the extent of the disease is such as to preclude complete surgical resection. In this situation radiotherapy is an option, however systemic therapy with targeted therapies or immune checkpoint inhibitors are increasingly an option. The possibility of a neoadjuvant approach to these patients with extensive disease has been proposed but at the present time must remain an investigational approach.

Notwithstanding the enormous strides that have been made with targeted therapies and immune checkpoint inhibitors for patients with metastatic disease, there is currently no evidence that these agents have a definitive role in the management of patients with lymph node field relapse. Numerous studies investigating a role for these agents are currently underway and where appropriate patients should be referred for possible participation in these studies.
Even with the widespread use of sentinel node biopsy (SNB) approximately 50% of patients with Stage III disease present with symptomatic, usually palpable or imaging detected lymph node field recurrence.[1] These patients include those who did not undergo SNB, patients who had a false negative SNB and patients presenting with lymph node field relapse and no known primary lesion. Lymph node field recurrence is the commonest and usually first site of recurrence of melanoma in patients not undergoing a SLNB. Patients with thick melanomas who did not undergo a SNB have a median time to presentation with a lymph node field recurrence of 9 months and for patients with intermediate thickness melanoma and no sentinel node biopsy around 19 months. However lymph node field recurrence many years after treatment of a primary lesion are a well-recognised but uncommon phenomenon.[1] Surgical management of patients presenting with macroscopic nodal disease results in a lymph node field results in long term control in nearly 50% of patients, however this varies widely depending on a number of factors including time since treatment of the primary lesion and features of the primary melanoma including thickness and ulceration.[1] The reported ten year survival of patients in the AJCC database is approximately 45% for patients with Stage III B disease (1-3 nodes involved)and approximately 25% for patients with Stage III C disease (more than 3 nodes involved).[2] As there is still a high risk of failure with surgical therapy there is great interest in the addition of effective systemic therapies to the management of these patients either in the adjuvant or neoadjuvant setting and clinical trials are currently underway.

The diagnosis should be confirmed pre-operatively preferably, by ultrasound guided fine needle aspirate (FNAC)) even for palpable lymphadenopathy rather than open biopsy (or core needle biopsy) which may potentially contaminate the operative site.

The risk for patients with clinical stage 3B/C disease of occult disseminated disease at presentation is approximately 20%. Preoperative staging preferably by PET-CT and MRI brain is therefore indicated.[3] Alternatively CT may be used. PET/CT however has superior sensitivity and specificity for staging compared to other imaging modalities. MRI brain is superior to standard CT brain.

Tumour markers (LDH, S100 etc) have not been shown to be particularly sensitive or specific in staging patients with stage III B/C disease nor useful in planning treatment or predicting outcome and are not recommended.

<table>
<thead>
<tr>
<th>Practice point</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients with macroscopic nodal disease should have the diagnosis confirmed preoperatively by image guided fine needle aspiration cytology and undergo staging with whole body PET-CT and MRI brain or CT Brain, Chest Abdomen and Pelvis.</td>
</tr>
</tbody>
</table>
5.2 Summary of systematic review results

Extensive observational data indicates surgical management of the lymph node field by radical lymphadenectomy results in long term control in up to 50% of patients. There is limited data available as to the extent of the surgery. Limited and indirect evidence favours radical comprehensive surgical procedures over less aggressive approaches. Special situations include patients presenting with lymphadenopathy and no prior history of a primary lesion (unknown primary). These patients achieve results comparable or better to those with a recognised primary lesion with standard surgical management.

5.3 Surgical treatment

Complete clearance of the involved lymph node field is indicated. There is little data available comparing radical clearance with lesser procedures. Higher rates of local recurrence and potentially worse survival have been noted following inadequate surgery. In a number of retrospective studies, the adequacy of the surgical procedure as determined by the number of lymph nodes removed and performance of the surgery in a high volume institution were associated with reduced risk of lymph nodes field relapse and distant relapse. More recently the Lymph Node Ratio (the number of involved to uninvolved nodes) has been shown to be related to both survival and regional recurrence presumably reflecting the completeness of the lymphadenectomy.

5.3.1 Cervical lymphadenectomy

The surgical options for management of cervical lymphadenopathy include radical neck dissection (removal of all nodes in levels I-V including sterno mastoid muscle, accessory nerve and internal jugular vein), extended radical (includes a superficial parotidectomy in addition), modified radical neck dissection (removal of all nodes in levels I-V with preservation of all or some of sterno mastoid muscle, accessory nerve and internal jugular vein) or selective node dissection (removal of less than levels I-V usually with preservation of major structures). In addition resection of occipital/retro-auricular nodes is indicated for primary melanomas located behind the plane of the external auditory canal, patients who had lymphatic mapping to the area but no SLNB found or patients with involved lymph nodes in this region.

Patients with a parotid lymph node field recurrence have a risk of upper cervical lymph node involvement of up to 20%. Surgical management of parotid lymphadenopathy should include parotidectomy and an upper level cervical lymphadenectomy (levels 1B, 2, 3, and upper 5 and possibly 1a).

Practice point

Patients with a parotid lymph node recurrence should undergo a superficial parotidectomy and upper neck dissection (levels 1B, 2, 3, and upper 5 and possibly 1a).
In principle the sterno mastoid muscle, accessory nerve or internal jugular vein should only be removed if involved with tumour or to facilitate complete resection. The role of selective lymphadenectomy is undetermined. At present for limited volume disease it appears to offer similar rates of regional and distant control to more aggressive procedures however for patients with more extensive disease i.e. N2, N3 disease higher rates of local recurrence in particular have been noted.[12][13]

5.3.2 Axillary lymphadenectomy

The standard procedure for axillary lymph node involvement is a complete level 1-3 lymphadenectomy which may include resection of the pectoralis minor muscle (to facilitate clearance of the superior axilla), intercosto-brachial nerve(s) and usually medial pectoral nerve dependent on the extent of disease and body habitus. Less extensive procedures may be associated with higher rates of regional recurrence.[14]

5.3.3 Inguinal lymphadenectomy

The surgical management of inguinal lymph node field relapse is controversial with proponents arguing for inguinal lymphadenectomy or combined inguinal and pelvic lymphadenectomy.[15][16] Pre-operative staging should involve a CT scan or PET / CT scan of the inguinal and pelvic lymph node fields to exclude the presence of pelvic lymph node involvement as 25 to 50% of patients undergoing combined inguinal and pelvic lymphadenectomy will have pelvic lymph node involvement.[15][17] Unfortunately the sensitivity and specificity of CT scanning in this situation is limited and there is limited data on the effectiveness of PET / CT scanning.[18][15] Intraoperative assessment of the risk of pelvic lymph node involvement based on femoral canal or Cloquet’s node status is unreliable. Tumour volume as determined by increasing number and size of inguinal nodes is associated with an increased risk of pelvic lymph node involvement but is of limited practical value for most cases.

Hesitation around recommending combined inguinal and pelvic lymphadenectomy reflects concerns about undertaking a more extensive and possibly more morbid procedure in the absence of a definite survival advantage. Unproven concerns about worse lymphoedema and poorer quality of life with the combined procedure has led most authorities to recommend inguinal and pelvic lymphadenectomy only for proven pelvic involvement or the presence of extensive inguinal disease. A prospective long term evaluation of symptoms, quality of life and limb volumes found no differences between inguinal and combined inguinal and pelvic lymphadenectomy. There is an ongoing randomised controlled trial evaluating the role of inguinal versus ilioinguinal lymphadenectomy in this situation.[19] This study is a proof of principle study that less extensive surgery is safe when the PET / CT scan is negative in the pelvic area. It is a lead into other surgical extent de-escalation studies, especially relevant in the era of impending effective neoadjuvant and / or adjuvant therapy.

5.3.4 Unknown primary melanoma

In approximately 10-15% of patients with palpable lymphadenopathy the site of the primary lesion cannot be identified. Possible explanations include a regressed primary melanoma or a melanoma arising within the lymph node itself. A complete skin examination should be performed and the pathology of any previous skin lesions reviewed. These patients should be worked up and treated in a similar fashion to patients with a recognised primary lesion. The outcomes for these patients is at least as good as for patients with an identifiable primary lesion.[20][21][22][23][24][25]
5.3.5 Uncommon lymph node recurrences

Occasionally patients may present with disease in the epi-trochlear or popliteal fossae. Palpable disease in these lymph node fields may be associated with involvement of the inguinal or axillary lymph node fields and should be investigated prior to resection. In a small number of cases patients may present with disease just outside the axillary or inguinal lymph node fields. Consideration should be given to resecting the palpable recurrence, the adjacent lymph node field and the intervening tissue (in continuity resection).

5.4 Adjuvant therapy

5.4.1 Adjuvant radiotherapy

Patients at high risk of lymph node field relapse after lymphadenectomy (at least 25%) include those with multiple nodes involved (1 parotid, >2 cervical or >3 axillary or inguinal), large lymph nodes (>3 cm) or extensive extra-capsular spread of tumour.[26] Adjuvant radiotherapy reduces the risk of lymph node field relapse by approximately 50% but does not improve survival. In addition radiotherapy is associated with worse long term regional symptoms and increased lymphoedema in the lower limb.[17] Patients who develop an isolated lymph node field relapse after lymphadenectomy alone can often be managed successfully by a combination of surgery and radiotherapy.[17][27]

5.4.2 Adjuvant systemic therapy

The use of adjuvant systemic therapies at the present time is highly controversial. Currently routine systemic therapy after lymphadenectomy cannot be recommended. Interferon alpha 2B (four week high dose induction therapy followed by 11 months maintenance therapy) is associated with a small improvement in survival (3% at five years) but with potential significant toxicity (Mocellin 2012). Initial results from a trial of ipilimumab (10 mg /kg) resulted in a modest improvement in survival but again at the risk of significant toxicity. Results from a number of other trials of BRAF and MEK inhibition, anti PD-1 immune modulation therapy as well as combinations of different agents are awaited.

5.5 Evidence summary and recommendations

<table>
<thead>
<tr>
<th>Evidence summary</th>
<th>Level</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lymphadenectomy provides long term control in up to 50% of patients with Stage III B and III C disease.</td>
<td>II</td>
<td>[2]</td>
</tr>
</tbody>
</table>
## 5.5.1 Recommendations

<table>
<thead>
<tr>
<th>Evidence-based recommendation</th>
<th>Grade</th>
</tr>
</thead>
<tbody>
<tr>
<td>Complete lymphadenectomy is recommended for patients with palpable or imaging detected lymph node field recurrence.</td>
<td>C</td>
</tr>
</tbody>
</table>

### Practice point

Complete lymphadenectomy results in improved regional control over lesser procedures.

### Practice point

All patients with Stage III B/C disease should be presented at a multidisciplinary management meeting.

### Practice point

These high risk patients should be offered the opportunity to enrol in systemic adjuvant or neoadjuvant therapy trials.

## 5.6 References


These guidelines have been developed as web-based guidelines and the pdf serves as a reference copy only. Please note that this material was published on 16:43, 6 April 2017 and is no longer current.


Back to top
5.1 Treatment of melanoma brain metastases

5.2 Systemic drug therapy for patients with brain metastases

COPY OF CONTENT UNTIL NEW CONTENT RECEIVED

5.2.1 Evidence from literature

Brain metastases are diagnosed in more than 50% of patients with advanced melanoma and are associated with a poor prognosis with a median OS of 2.8 to 4 months.\textsuperscript{[1]}\textsuperscript{[2]} Phase III trials of effective drug therapies have excluded patients with active central nervous system (CNS) metastases, except for specifically designed phase II studies, summarised below. There were no new toxicities observed in this population of active melanoma brain metastases.

A phase 2 trial of the anti-CTLA-4 checkpoint inhibitor ipilimumab (10mg/kg for four doses) demonstrated an intracranial response of 16% (8/51) in neurologically asymptomatic patients (cohort A) but only a 5% (1/21) intracranial response rate in symptomatic (cohort B) patients requiring corticosteroids.\textsuperscript{[3]}

In a small study patients with active melanoma brain metastases treated with the anti-PD-1 checkpoint inhibitor pembrolizumab, the intracranial response was 22% (4/18).\textsuperscript{[4]} Similarly, in the larger randomised phase II Australian Brain Collaboration (ABC) study the intracranial response rate in asymptomatic patients with
untreated brain metastases was 21% (5/25) with nivolumab monotherapy, but higher at 46% (16/35) with ipilimumab combined with nivolumab, and 56% for the combination when patients had no prior BRAF and MEK inhibitors. The 12-month landmark PFS for each cohort was 20% and 53% respectively, with a plateau in the Kaplan Meier survival curve at approximately 6 months, raising the possibility that a significant proportion of patients may experience long-term disease control. A US single-arm study of the combination of ipilimumab and nivolumab in patients with asymptomatic melanoma brain metastases showed an intracranial response rate of 55% in the brain and a landmark 6-month PFS of 67%, although the burden of brain metastases in this trial was lower than that of the ABC trial (proportion of patients with > 3 brain metastases 21% versus > 4 brain metastases 46% in ABC).

Phase II trials of BRAF inhibitor monotherapy for V600 mutant melanoma demonstrated an intracranial response of 39% for dabrafenib and 29% for vemurafenib as assessed by the investigators. The combination the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib was assessed in a phase II trial of four different cohorts of V600 BRAF-mutation positive patients with active melanoma brain metastases. The intracranial response rate was 58% in the largest cohort (n=76, cohort A), which included neurologically asymptomatic patients without previous local (brain) therapy. In contrast to the results with anti-PD-1-based immunotherapy, the PFS decreased over the first 12 months from 44% at 6-months to 19% at 12-months, suggesting that responses are short-lived as patients develop resistance.

As there are now many treatment options for the management of melanoma brain metastases, patients are strongly recommended to be discussed by an expert multi-disciplinary team of clinicians including a neurosurgeon, radiation oncologist and medical oncologist to determine the optimal combination or sequencing of both local (surgery and stereotactic radiosurgery) and systemic therapies. Whole brain radiotherapy is now rarely used, often reserved as last line palliative therapy.

5.2.2 Evidence summary

<table>
<thead>
<tr>
<th>Evidence summary</th>
<th>Level</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Combined therapy with a BRAF inhibitor and MEK inhibitor induce an intracranial response of 58% in patients with asymptomatic untreated brain metastases whose melanoma has a V600E BRAF mutation.</td>
<td>III-1</td>
<td>[9]</td>
</tr>
<tr>
<td>Anti-PD-1 monotherapy in drug treatment naïve patients induces an intracranial response in at least 20% of patients with active melanoma brain metastases.</td>
<td>III-1</td>
<td>[4], [5]</td>
</tr>
<tr>
<td>Combined ipilimumab and nivolumab in drug treatment naïve patients induces an intracranial response in approximately 55% of patients with active brain metastases. (In drug-treatment naïve patients, phase II studies demonstrated a 56% and 55% intracranial response rate in the Australian Brain Collaboration and the CheckMate 204 studies, respectively, with a 6-month PFS rate of 53% and 67%, respectively).</td>
<td>III-1</td>
<td>[5], [6]</td>
</tr>
<tr>
<td>41-Tawbi et al 2018, awaiting PMID</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Drug therapy is active in untreated melanoma brain metastases, and can be considered as first line treatment (as an alternative to local brain therapy) in asymptomatic patients with multidisciplinary support with a radiation oncologist and neurosurgeon.

5.2.3 References


5.3 Surgical treatment of brain metastases

5.4 Radiotherapy for patients with brain metastases

5.5 Summary of recommendations and practice points

Summary of recommendations and practice points

5.6 Adjuvant systemic therapy – resected stage II and III melanoma

Content to be developed

Appendices
5.7 Systemic drug therapy – unresectable stage IIIC and IV melanoma

Appendices

View recommendation components
View pending evidence
View body of evidence
View all comments
View literature search

View PICO

5.8 Immunotherapy

Add content

5.9 Targeted therapies (MEK and BRAF inhibitors)

Add content

5.10 Chemotherapy
5.11 Summary of recommendations and practice points

5.12 Radiotherapy for distant metastases

Appendices

5.13 Radiotherapy following resection of involved lymph nodes
Appendices

6 Management of mucosal melanoma

Redirect to:
- Guidelines: Melanoma/Mucosal melanoma

7 Management of ocular melanoma

Intro to be inserted

8 Multidisciplinary care of melanoma patients

Content to be inserted.

8.1 References
8.1 Guideline development process

Contents

1 Background
2 Project governance, guidelines scope and guidelines development group
3 Guidelines development approach
4 Steps in preparing clinical practice guidelines
   4.1 Step 1. Develop a structured clinical question
   4.2 Step 2. Search for existing relevant guidelines and systematic reviews
   4.3 Step 3. Perform systematic review process
      4.3.1 Step 3a. If no relevant clinical practice guideline was found
         4.3.1.1 Developing a systematic search strategy
         4.3.1.2 Conducting the systematic literature search according to protocol
         4.3.1.3 Screening of literature results against pre-defined inclusion and exclusion criteria
         4.3.1.4 Critical appraisal and data extraction of each included article
      4.3.2 Step 3b. If a relevant clinical practice guideline was found and assessed as suitable for adaption
         4.3.2.1 Screening of literature update results against pre-defined inclusion and exclusion criteria
         4.3.2.2 Critical appraisal and data extraction of each included article
   4.4 Step 4. Summarise the relevant data
      4.4.1 Table 1. Designations of levels of evidence according to type of research question (NHMRC, 2009)
   4.5 Step 5. Assess the body of evidence and formulate recommendations
      4.5.1 Table 2. Grading of recommendations
      4.5.2 Table 3. Overall recommendation grades
      4.5.3 Table 4. NHMRC approved recommendation types and definitions
   4.6 Step 6. Write the content narrative

These guidelines have been developed as web-based guidelines and the pdf serves as a reference copy only. Please note that this material was published on 16:43, 6 April 2017 and is no longer current.
8.1.1 Background

In 2014, Cancer Council Australia and Melanoma Institute Australia partnered as guideline developers and initiated the project to revise the Clinical Practice Guidelines for the Management of Melanoma in Australia and New Zealand. Due to the advancements in treatment options, the 2008 guidelines are no longer up to date. The evidence base and management of melanoma has significantly changed since 2008, particularly for the treatment of stage III and stage IV disease emerging over the past few years. Importantly, targeted and systemic therapy drugs are now registered for use within Australia and there are significant publications demonstrating the improvement for life expectancy in melanoma patients due to the improved treatment options.

Cancer Council Australia and Melanoma Institute Australia contributed in kind resources consisting of project staff, facilities, systems and travel budget to revise the 2008 guidelines. In 2015, Skin Cancer College Australasia joined the project and provided funding to enable employment of an additional full-time Project Officer in the Systematic Review team.

8.1.2 Project governance, guidelines scope and guidelines development group

Cancer Council Australia and Melanoma Institute Australia appointed a small Management Committee that were members of the 2008 working party, to oversee the guidelines revision project (see working party members and contributors). The Management Committee is responsible for the overall management and strategic leadership of the guidelines review process. This includes the establishment of the wider multidisciplinary guidelines working party and question-specific sub-committee members in consultation with the lead authors and the evaluation of declarations of interest and, if necessary, implementing management strategies for conflict/s of interest.

During a face-to-face meeting in November 2014, the Management Committee assessed the clinical questions addressed the 2008 guidelines and determined the priority clinical questions to be included in this revision. Twenty-three questions were identified to be of greatest importance, covering issues related to diagnosis, staging and management of cutaneous melanoma (see list of clinical questions).

The Management Committee proposed lead authors for each included clinical question. The nominated individuals were invited to join the (see multidisciplinary working party). In addition, the Management Committee identified and nominated two consumer representatives and two GP representatives to join the multidisciplinary working party.
In consultation with the question lead author, sub-committees consisting of members with relevant expertise and experience were established for each question (see multidisciplinary working party).

Declarations of interest were collected from all nominated members and evaluated (see COI register). All members were advised to update their declarations of interest over the course of the project and received reminders to review their declarations prior to every formal working party meeting.

Back to top

8.1.3 Guidelines development approach

The Management Committee agreed to use Cancer Council Australia’s Cancer Guidelines Wiki Platform and approach to develop the guidelines. The Wiki Platform is web-based and supports all processes of guidelines development, such as the literature search, critical appraisal, data extraction, evidence assessment and summary processes, as well as content and recommendation development, online consultation, review and web publication. It is in line with the NHMRC guidelines requirements, designated standards of quality, process and grading system for recommendations.\(^1\)^\(^2\) An infrastructure is set in place to process literature updates and continuously update content as new evidence emerges and is reviewed.

The Development of Clinical Practice Guidelines using Cancer Council Australia’s Cancer Guidelines Wiki Handbook\(^3\) illustrates the steps in the development of Cancer Council Australia’s web-based clinical practice guidelines. It provides information to assist working party members and staff members to develop concise clinical questions in PICO format, construct sound search strategies, systematically search the literature, critically appraise, summarise the evidence and formulate guidelines recommendations.

The Management Committee was approached by the German guidelines development group, which developed the guidelines “Malignant Melanoma S3-Guideline Diagnosis, Therapy and Follow-up of Melanoma”\(^4\) in 2012 and adapted some sections from the 2008 Australian guidelines. The systematic review team assessed the German guidelines using the AGREE II assessment tool\(^5\) and found the guidelines to be high quality. As many exhaustive systematic reviews were undertaken to answer critical clinical questions in the melanoma diagnosis and management guidelines, it was decided to adapt the German systematic reviews and update the literature searches, where possible, rather than undertaking new systematic reviews for the same clinical questions (see also 3b. If a relevant clinical practice guidelines was found and assessed as suitable for adaption). The data extractions and quality appraisals of any new studies will be shared with the German group.

Rather than waiting until systematic reviews and content for all included clinical questions have been finalised, the Management Committee agreed to publish finalised question content and the associated recommendations in stages. The group decided that it is important to publish content and results as soon as it is finalised by the working party to ensure that the medical community receives up-to-date information without any publication delay. Prior to publication, feedback would be sought from guidelines stakeholders about the clinical questions content (See also Public consultation).
The first set of completed draft contents is now being released for public consultation (refer to set of questions).

- What are the clinical features of melanoma and how do atypical melanomas present?
- What type of biopsy should be performed for a suspicious pigmented skin lesion?
- When is a sentinel node biopsy indicated?
- What are the recommended safety margins for radical excision of primary melanoma?

Subsequent clinical questions and associated recommendations will be published in 2016 and 2017.

The detailed steps in preparing the question content, conducting the literature searches, appraising the literature and formulating and grading recommendations, are outlined below.

Back to top

8.1.4 Steps in preparing clinical practice guidelines

For every clinical question the following steps were completed:

1. Develop a structured clinical question in PICO format

2. Search for existing relevant guidelines and systematic reviews answering the clinical question

3. Perform systematic review process, depending on if a relevant clinical practice guideline is identified or not

<table>
<thead>
<tr>
<th>3a If no relevant clinical practice guideline was found</th>
<th>3b If a relevant clinical practice guideline was found and assessed as suitable for adaption</th>
</tr>
</thead>
<tbody>
<tr>
<td>Developing the systematic review protocol and systematic literature search strategy for each PICO question</td>
<td></td>
</tr>
<tr>
<td>Conducting the systematic literature search according to protocol</td>
<td></td>
</tr>
<tr>
<td>Screening of literature results against pre-defined inclusion and exclusion criteria</td>
<td></td>
</tr>
<tr>
<td>Critical appraisal and data extraction of each included article</td>
<td></td>
</tr>
<tr>
<td>Create body evidence table of all included literature</td>
<td></td>
</tr>
<tr>
<td>Undertake systematic literature search update for the question of the existing clinical practice guideline</td>
<td></td>
</tr>
<tr>
<td>Screening of literature update results against pre-defined inclusion and exclusion criteria</td>
<td></td>
</tr>
<tr>
<td>Critical appraisal and data extraction of each new included article</td>
<td></td>
</tr>
<tr>
<td>Update body evidence table of evidence review of existing guideline with new literature update results</td>
<td></td>
</tr>
</tbody>
</table>
4. Summarise the relevant data

5. Assess the body of evidence and formulate recommendations

6. Write the content narrative

Back to top

8.1.4.1 Step 1. Develop a structured clinical question

All included questions were reviewed on the basis of their purpose, scope and clinical importance to the target audience and were structured according to the PICO (populations, interventions, comparisons, outcomes) framework. The lead authors provided the systematic review team with feedback to refine the PICO questions and inclusion and exclusion criteria for the systematic review.

Back to top

8.1.4.2 Step 2. Search for existing relevant guidelines and systematic reviews

For each PICO question, the National Guideline Clearinghouse, the Guidelines Resource Centre and the scoping search for the PICO question were scanned for relevant clinical practice guidelines that could potentially be suitable for adaption.

Full systematic reviews were then performed as outlined in the sections below (Developing a systematic search strategy; Conducting the systematic literature search according to protocol; Screening of literature results against pre-defined inclusion and exclusion criteria; Critical appraisal and data extraction of each included article).

If an existing relevant guideline was identified, the guideline was assessed with the AGREEII assessment tool[5] to ensure the guideline is of high quality. The ADAPTE process was then followed.[6]

Back to top

8.1.4.3 Step 3. Perform systematic review process

8.1.4.3.1 Step 3a. If no relevant clinical practice guideline was found

8.1.4.3.1.1 Developing a systematic search strategy

For each PICO question, systematic literature search strategies were developed by the technical team. Searches were limited or widened as necessary according to the PICO structure using keywords or MESH and subject terms. Systematic search strategies were derived from these terms for each included electronic databases. The included standard databases searched were Pubmed, Embase, Trip database, Cochrane Database of Systematic Reviews and Database of Abstracts of Reviews of Effects and Health Technology Assessment for all questions. The psychosocial questions also included CINAHL and PsycINFO databases to retrieve relevant literature.
8.1.4.3.1.2 Conducting the systematic literature search according to protocol

Clinical practice guidelines should be based on systematic identification and synthesis of the best available scientific evidence.\(^1\) For each clinical question that required a systematic literature review, literature searches were conducted systematically from 2007 onwards. The following electronic databases were part of the systematic literature search strategy:

- **PubMed** - bibliographic references and abstracts to articles in a range of languages on topics such as clinical medical information and biomedicine, and including the allied health fields, biological and physical sciences.
- **EMBASE** - major pharmacological and biomedical database indexing drug information from 4550 journals published in 70 countries.
- **Trip Database** - A medical database with focus on Evidence based medicine and clinical practice guidelines with content available from Cochrane and Bandolier.
- **Database of Abstracts of Reviews of Effects and Health Technology Assessment** - Contains details of systematic reviews that evaluate the effects of healthcare interventions and the delivery and organisation of health services.
- **The Cochrane Database of Systematic Reviews**.
- **Cinahl** - Bibliographic references and abstracts to journal articles, book chapters, pamphlets, audiovisual materials, software, dissertations, critical paths, and research instruments on topics including nursing and allied health, biomedicine, consumer health, health sciences librarianship, behavioral sciences, management, and education
- **Psychinfo** - Bibliographic references and abstracts to journal articles, book chapters, dissertations and technical reports on psychology; social, clinical, cognitive and neuropsychology; psychiatry, sociology, anthropology and education, with source material from a wide range of languages.

Additional relevant papers from reference lists and, where appropriate, clinical trial registries, were also identified for retrieval as part of the snowballing process.

The full detailed systematic literature search strategy for every clinical question is fully documented in the appendix of the clinical question.

8.1.4.3.1.3 Screening of literature results against pre-defined inclusion and exclusion criteria

Part of the systematic review process is to screen all retrieved literature results against the pre-defined inclusion and exclusion criteria in two stages.
a) **First screen** - During the first screening round, the titles and abstracts of all retrieved literature were screened by one reviewer. All irrelevant, incorrect and duplicates were removed.

b) **Second screen** - A second screen was undertaken based on the full article. Two reviewers assessed each article for inclusion against the pre-defined inclusion and exclusion criteria for each question. In the case of a disagreement between the reviewers, a third independent reviewer assessed the article against the inclusion and exclusion criteria. Articles that met the inclusion criteria were forwarded for quality assessment and data extraction.

**8.1.4.3.1.4 Critical appraisal and data extraction of each included article**

Two assessors independently assessed the risk of bias of each of the included studies using a study design specific assessment tool and where necessary pre-specified criteria. For all quality assessment tools, see link to pdf.

Any disagreements were adjudicated by a third reviewer.

For all included articles, the relevant data was extracted and summarised in study characteristics and evidence tables. Each data extraction was checked by a second assessor. These tables are available in the appendix of each question.

**8.1.4.3.2 Step 3b. If a relevant clinical practice guidelines was found and assessed as suitable for adaption**

Undertake systematic literature search update for the question of the existing clinical practice guideline If an existing clinical practice guideline of high quality was found that directly addresses the clinical question to be reviewed, an update search of the original systematic literature search was performed covering the time period between the literature cut-off of the original review until now across all relevant databases (see also Conducting the systematic literature search according to protocol).

**8.1.4.3.2.1 Screening of literature update results against pre-defined inclusion and exclusion criteria**

All retrieved literature results from the update search were screened against the pre-defined inclusion and exclusion criteria in two stages.

a) **First screen** - During the first screening round, the titles and abstracts of all retrieved literature were screened by 1 reviewer. All irrelevant, incorrect and duplicates were removed.
b) Second screen - A second screen was undertaken based on the full article. Two reviewers assessed each article for inclusion against the pre-defined inclusion and exclusion criteria for each question. In the case of a disagreement between the reviewers, a third independent reviewer assessed the article against the inclusion and exclusion criteria. Articles that met the inclusion criteria were forwarded for quality assessment and data extraction.

Back to top

8.1.4.3.2.2 Critical appraisal and data extraction of each included article

Two assessors independently assessed the risk of bias of each of the included studies using a study design specific assessment tool and where necessary pre-specified criteria. For all quality assessment tools, see link to pdf.

Any disagreements were adjudicated by a third reviewer.

Back to top

8.1.4.4 Step 4. Summarise the relevant data

The study results, level of the evidence, risk of bias due to study design and the relevance of the evidence for each included study were summarised in a body of evidence table.

When a systematic review from an existing guidelines was updated to answer and develop recommendations for a clinical question, the new evidence was added to the existing body of evidence table. Where required, the levels of evidence were translated to the NHMRC levels of evidence. The NHMRC levels of evidence are outlined below:

8.1.4.4.1 Table 1. Designations of levels of evidence according to type of research question (NHMRC, 2009)

<table>
<thead>
<tr>
<th>Level</th>
<th>Intervention</th>
<th>Diagnosis</th>
<th>Prognosis</th>
<th>Aetiology</th>
<th>Screening</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>A systematic review of level II studies</td>
<td>A systematic review of level II studies</td>
<td>A systematic review of level II studies</td>
<td>A systematic review of level II studies</td>
<td>A systematic review of level II studies</td>
</tr>
<tr>
<td>II</td>
<td>A randomised</td>
<td>A study of test accuracy with: an independent, blinded comparison with a valid reference standard,</td>
<td>A prospective</td>
<td>A prospective</td>
<td>A randomised</td>
</tr>
<tr>
<td>III-1</td>
<td>controlled trial</td>
<td>among consecutive patients with a defined clinical presentation</td>
<td>cohort study</td>
<td>cohort study</td>
<td>controlled trial</td>
</tr>
<tr>
<td>-------</td>
<td>------------------</td>
<td>-------------------------------------------------</td>
<td>--------------</td>
<td>--------------</td>
<td>-----------------</td>
</tr>
<tr>
<td></td>
<td>A pseudo-randomised controlled trial (i.e. alternate allocation or some other method)</td>
<td>A study of test accuracy with: an independent, blinded comparison with a valid reference standard, among non-consecutive patients with a defined clinical presentation</td>
<td>All or none</td>
<td>All or none</td>
<td>A pseudo-randomised controlled trial (i.e. alternate allocation or some other method)</td>
</tr>
</tbody>
</table>
|       | A comparative study with concurrent controls:  
  Non-randomised, experimental trial  
  Cohort study  
  Case-control study  
  Interrupted time series with a control group | A comparison with reference standard that does not meet the criteria required for Level II and III-1 evidence | Analysis of prognostic factors amongst untreated control patients in a randomised controlled trial | A retrospective cohort study | A comparative study with concurrent controls:  
  Non-randomised, experimental trial  
  Cohort study  
  Case-control study |
|       | A comparative study without concurrent controls:  
  Historical control study  
  Two or more single arm study | Diagnostic case-control study | A retrospective cohort study | A case-control study | A comparative study without concurrent controls:  
  Historical control study |
Clinical practice guidelines for the diagnosis and management of melanoma

<table>
<thead>
<tr>
<th>IV</th>
<th>Case series with either post-test or pre-test/post-test outcomes</th>
<th>Study of diagnostic yield (no reference standard)</th>
<th>Case series, or cohort study of patients at different stages of disease</th>
<th>A cross-sectional study</th>
<th>Two or more single arm study</th>
</tr>
</thead>
</table>


Back to top

8.1.4.5 Step 5. Assess the body of evidence and formulate recommendations

The body of evidence table for each clinical question was forwarded to the lead author for assessment. The lead author in collaboration with the systematic reviewer (who conducted the systematic reviews and extracted the data and performed risk of bias assessment) assessed the body of evidence and completed the evidence assessment matrix in regard to the volume of the evidence, its consistency, clinical impact, generalisability and applicability and developed evidence statements for each recommendation.

The process is described in NHMRC additional levels of evidence and grades for recommendations for developers of guidelines (2009).[7]

Following grading of the body of evidence and development of evidence statements, authors were asked to formulate evidence-based recommendations based on the results of the systematic review summarised in the body of evidence table. The method of grading recommendations is shown in Table 2.

8.1.4.5.1 Table 2. Grading of recommendations

<table>
<thead>
<tr>
<th>Component of Recommendation</th>
<th>Recommendation Grade</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>A</td>
</tr>
<tr>
<td></td>
<td>Excellent</td>
</tr>
<tr>
<td>one or more level I studies with</td>
<td>one or two level II studies with</td>
</tr>
</tbody>
</table>
## Volume of evidence

<table>
<thead>
<tr>
<th>Level</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>1**</td>
<td>a low risk of bias or several level II studies with a low risk of bias</td>
</tr>
<tr>
<td></td>
<td>low risk of bias or a systematic review/several level III studies with a low risk of bias</td>
</tr>
<tr>
<td></td>
<td>studies with a low risk of bias, or level I or II studies with a moderate risk of bias</td>
</tr>
<tr>
<td></td>
<td>level I to III studies/systematic reviews with a high risk of bias</td>
</tr>
</tbody>
</table>

## Consistency

<table>
<thead>
<tr>
<th>Level</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>2**</td>
<td>all studies consistent</td>
</tr>
<tr>
<td></td>
<td>most studies consistent and inconsistency may be explained</td>
</tr>
<tr>
<td></td>
<td>some inconsistency reflecting genuine uncertainty around clinical question</td>
</tr>
<tr>
<td></td>
<td>evidence is inconsistent</td>
</tr>
</tbody>
</table>

## Clinical impact

<table>
<thead>
<tr>
<th>Level</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>very large</td>
<td></td>
</tr>
<tr>
<td>substantial</td>
<td></td>
</tr>
<tr>
<td>moderate</td>
<td></td>
</tr>
<tr>
<td>slight or restricted</td>
<td></td>
</tr>
</tbody>
</table>

## Generalisability

<table>
<thead>
<tr>
<th>Description</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>population/s studied in body of evidence are the same as the target population for the guideline</td>
<td></td>
</tr>
<tr>
<td>population/s studied in the body of evidence are similar to the target population for the guideline</td>
<td></td>
</tr>
<tr>
<td>population/s studied in body of evidence differ to target population for guideline but it is clinically sensible to apply this evidence to target population</td>
<td></td>
</tr>
<tr>
<td>population/s studied in body of evidence different to target population and hard to judge whether it is sensible to generalise to target population</td>
<td></td>
</tr>
</tbody>
</table>

## Applicability

<table>
<thead>
<tr>
<th>Description</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>directly applicable to Australian healthcare context</td>
<td></td>
</tr>
<tr>
<td>applicable to Australian healthcare context with few caveats</td>
<td></td>
</tr>
<tr>
<td>probably applicable to Australian healthcare context with some caveats</td>
<td></td>
</tr>
<tr>
<td>not applicable to Australian healthcare context</td>
<td></td>
</tr>
</tbody>
</table>

1 Level of evidence determined from level of evidence criteria

2 If there is only one study, rank this component as ‘not applicable’

3 For example results in adults that are clinically sensible to apply children OR psychosocial outcomes for one cancer that may be applicable to patients with another cancer.

**For a recommendation to be graded A or B, the volume and consistency of evidence must also be graded either A or B!

The overall recommendations grade are shown in Table 3.

### 8.1.4.5.2 Table 3. Overall recommendation grades

<table>
<thead>
<tr>
<th>Grade of recommendation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>Body of evidence can be trusted to guide practice</td>
</tr>
<tr>
<td>B</td>
<td>Body of evidence can be trusted to guide practice in most situations</td>
</tr>
<tr>
<td>C</td>
<td>Body of evidence provides some support for recommendation(s) but care should be taken in its application</td>
</tr>
<tr>
<td>D</td>
<td>Body of evidence is weak and recommendation must be applied with caution</td>
</tr>
</tbody>
</table>


The NHMRC approved recommendation types and definitions are shown in Table 4.

### 8.1.4.5.3 Table 4. NHMRC approved recommendation types and definitions

<table>
<thead>
<tr>
<th>Type of recommendation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Evidence-based recommendation</td>
<td>A recommendation formulated after a systematic review of the evidence, indicating supporting references</td>
</tr>
<tr>
<td>Consensus-based recommendation</td>
<td>A recommendation formulated in the absence of quality evidence, after a systematic review of the evidence was conducted and failed to identify admissible evidence on the clinical question</td>
</tr>
<tr>
<td>Practice point</td>
<td>A recommendation on a subject that is outside the scope of the search strategy for the systematic review, based on expert opinion and formulated by a consensus process</td>
</tr>
</tbody>
</table>

*Source: National Health and Medical Research Council. Procedures and requirements for meeting the NHMRC standard for clinical practice guidelines. Melbourne: National Health and Medical Research Council, 2011*

In addition to developing evidence-based recommendations as a result of the systematic review for a clinical question, expert authors could also draft consensus-based recommendations in the absence of evidence after having performed a systematic review or practice points, when a matter was outside the scope of the search strategy for the systematic review.
8.1.4.6 Step 6. Write the content narrative

For each question, the assigned lead authors were asked to draft their guidelines chapter using the following format:

- Background to the clinical question, including its clinical importance and historical evidence, where relevant
- Review of the evidence, including the number, quality and findings of studies identified by the systematic review
- Evidence summary in tabular form including evidence statements, levels of evidence of included studies, and reference citations
- Evidence-based recommendation(s) and corresponding grade(s), consensus-based recommendations and practice points
- Discussion, including unresolved issues, relevant studies currently underway, and future research priorities
- References.

The content draft was then reviewed by all sub-committee members. The draft documents underwent several iterations until agreement between the members of the sub-committee on these drafts was reached.

Back to top

8.1.5 Review of the draft chapters

Each set of draft content was circulated to the Working Party. The whole group was asked to review the content and submit feedback. Members were asked to submit further suggestions on consensus-based recommendation and practice points.

A face-to-face meeting with all working party members was scheduled to review and finalise the draft content for public consultation. Prior to this meeting, the latest iteration drafts were circulated. All panelists were asked to review the content, individual recommendations and practice points in detail, identify and note any controversies and points to be discussed at the meeting. During the meeting, each recommendation and practice point was tabled as an agenda point. Each was reviewed and approved by consensus, which was reached by voting. The Chairperson nominated a particular recommendation/practice point to be reviewed and the panelists had the opportunity to discuss any issues and suggest revisions to recommendations and practice points. Each recommendation and practice point was approved once the eligible panelists reached consensus.

Back to top

8.1.6 Public consultation

This guideline is being developed in a staged process.

- The first set of draft clinical questions (Features of Melanoma, Biopsy, Sentinel Node Biopsy, Excision Margins) were made available on the wiki for public consultation from 14 May to 14 June 2016.

- The second set of draft clinical questions (Diagnostic aids for melanoma (Dermoscopy) and Confocal microscopy) were made available on the wiki for public consultation from 23 January to 17 February 2017.
During each public consultation period, submissions were invited from the general public and professional societies and groups and other relevant stakeholders. Relevant professional societies and groups, consumer groups and other relevant stakeholders were contacted.

All feedback on the draft received during the consultation periods were compiled and sent to the relevant lead author (and subcommittee, when required) to review the draft content, assessing and considering the submitted comments. Any additional submitted paper during public consultation was assessed by the methodologist team against the review protocol.

Wider Working Party review of the public consultation comments and suggested amendments was facilitated by email or teleconference. Subsequent changes to the draft were agreed by consensus, based on consideration of the evidence and, in the absence of evidence, expert opinion. The same consensus process that was followed during the face-to-face working party meeting prior to public consultation was followed again. All changes resulting from the public consultation submission reviews will be documented and made accessible by request once the guidelines are published.

8.1.7 Dissemination and implementation

A multi-strategy approach will be followed for the dissemination and implementation of the guidelines, as this has shown to positively influence guidelines uptake.[8][9]

Once all clinical questions that are part of the guidelines revision are completed, the guidelines will be distributed directly to relevant professional and other interested groups and through meetings, national and international conferences, and other professional development and continuing medical education (CME) events. Local expert leaders will be identified and approached to facilitate dissemination and act as champions for the guidelines.

A significant effort will be made to have the guidelines introduced to senior undergraduate medical students and to encourage the relevant learned colleges to support the guidelines and to foster their integration into hospital and community practice through resident and registrar education activities.

The guidelines will be made available as online guidelines via the Cancer Council Australia Cancer Guidelines Wiki. The online guidelines version increases availability as well as accessibility, and usage will be tracked and analysed with a web analytics solution. The Cancer Guidelines Wiki is a responsive website that is optimised for mobile and desktop access.

Interlinking and listing the guidelines on national and international guideline portal is also an important part of the digital dissemination strategy. Important Australian health websites, such as EviQ and healthdirect Australia will be approached to link to the online guidelines. The guidelines will also be listed on national and international guideline portals such as Australia’s Clinical Practice Guidelines Portal, Guidelines International Network guidelines library and National Guidelines Clearinghouse.

The Cancer Guidelines Wiki is based on semantic web technology, so the guidelines are available in a machine-readable format, which offers the possibility to easily integrate the guidelines content with systems and web applications used in the Australian healthcare context. Use of the guidelines as part of core curriculum in specialty exams will be encouraged.
It is recognised that a planned approach is necessary to overcome specific barriers to implementation in particular settings and to identify appropriate incentives to encourage uptake of guidelines recommendations. Implementation of the guidelines will require a combination of effective strategies and may include further CME initiatives and interactive learning, the development and promotion of computer-assisted decision aids and electronic decision-support systems, and the creation of audit and other clinical tools.

8.1.8 Future updates

The Development of Clinical Practice Guidelines Using Cancer Council Australia’s Cancer Guidelines Wiki: Handbook for section authors and the guideline working party outlines Cancer Council Australia’s guidelines updating processes. The incoming literature updates will continue to be monitored for each systematic review question. The Working Party will notify the Technical Team if any clinical question requires revision because new high level evidence has been published. External stakeholders are encouraged to use the comment feature and notify us of any new evidence for a specific topic.

8.1.9 References

1. †1.0 1.1 National Health and Medical Research Council. Procedures and requirements for meeting the NHMRC standard for clinical practice guidelines. Melbourne; 2011.

These guidelines have been developed as web-based guidelines and the pdf serves as a reference copy only. Please note that this material was published on 16:43, 6 April 2017 and is no longer current.


Back to top

8.2 Working party members and contributors

<table>
<thead>
<tr>
<th>Member name</th>
<th>Position</th>
</tr>
</thead>
<tbody>
<tr>
<td>Professor John Thompson AO</td>
<td>Executive Director, Melanoma Institute Australia (until December 2016); Senior Surgeon, Melanoma Institute Australia; Professor of Melanoma and Surgical Oncology, The University of Sydney</td>
</tr>
<tr>
<td>Professor Michael Henderson</td>
<td>Professor of Surgery, University of Melbourne; Co-Chair, Melanoma and Skin Service, Peter MacCallum Cancer Centre, VIC</td>
</tr>
<tr>
<td>Professor John Kelly</td>
<td>Dermatologist and Head, Victorian Melanoma Service, Alfred Hospital</td>
</tr>
<tr>
<td>Professor Georgina Long</td>
<td>Co-Medical Director, Melanoma Institute Australia (from December 2016); Medical Oncologist and Associate Professor of Melanoma Biology and Translational Research, Melanoma Institute Australia and The University of Sydney, NSW</td>
</tr>
</tbody>
</table>
Clinical practice guidelines for the diagnosis and management of melanoma

<table>
<thead>
<tr>
<th>Member name</th>
<th>Position</th>
</tr>
</thead>
<tbody>
<tr>
<td>A/Professor Susan Neuhaus</td>
<td>General Surgeon and Surgical Oncologist, Royal Adelaide Hospital; Clinical Associate Professor, University of Adelaide Department of Surgery; Associate Professor, Conflict Medicine, University of Adelaide, SA</td>
</tr>
<tr>
<td>Dr Annette Pflugfelder</td>
<td>PhD Student, Dermatology Research Centre, School of Medicine, The University of Queensland</td>
</tr>
<tr>
<td>Professor Richard Scolyer</td>
<td>Co-Medical Director, Melanoma Institute Australia (from December 2016); Clinical Professor, Pathology, The University of Sydney, NSW</td>
</tr>
<tr>
<td>Professor Graham Stevens</td>
<td>Director of Radiation Oncology, Orange General Hospital, NSW</td>
</tr>
<tr>
<td>Jutta von Dincklage</td>
<td>Head, Clinical Guidelines Network (until November 2016)</td>
</tr>
<tr>
<td>Laura Wuellner</td>
<td>Acting Head, Clinical Guidelines Network (from November 2016)</td>
</tr>
</tbody>
</table>

For details of Working Party authorship and subcommittee membership, please see the List of clinical questions.

### 8.2.3 Membership: Multi-disciplinary Working Party

The Management Committee established a multi-disciplinary working party to develop these guidelines.

The multi-disciplinary Working Party consists of the Management Committee members, the lead authors for guideline sections, consumer representatives as well as the Cancer Council Australia Project team members.

<table>
<thead>
<tr>
<th>Role</th>
<th>Member name</th>
<th>Specialty/position</th>
<th>State</th>
</tr>
</thead>
<tbody>
<tr>
<td>Management Committee member, Chair of working party</td>
<td>Professor John Thompson AO</td>
<td>Executive Director, Melanoma Institute Australia (until December 2016); Senior Surgeon, Melanoma Institute Australia; Professor of Melanoma and Surgical Oncology, The University of Sydney</td>
<td>NSW</td>
</tr>
<tr>
<td>Lead Author</td>
<td>A/Professor Andrew Barbour</td>
<td>General Surgeon, Greenslopes Private Hospital, Princess Alexandra Hospital, QLD</td>
<td>QLD</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Medical Oncologist Westmead and Blacktown Hospitals, Melanoma institute Australia</td>
<td></td>
</tr>
</tbody>
</table>

These guidelines have been developed as web-based guidelines and the pdf serves as a reference copy only. Please note that this material was published on 16:43, 6 April 2017 and is no longer current.
Clinical practice guidelines for the diagnosis and management of melanoma

<table>
<thead>
<tr>
<th>Role</th>
<th>Member name</th>
<th>Specialty/position</th>
<th>State</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lead Author</td>
<td>Dr Matteo Carlino</td>
<td>Clinical Senior lecturer University of Sydney</td>
<td>NSW</td>
</tr>
<tr>
<td>Lead Author</td>
<td>Dr David Gyorki</td>
<td>Consultant Surgeon, Peter MacCallum Centre</td>
<td>VIC</td>
</tr>
<tr>
<td>Management Committee member</td>
<td>Professor Michael Henderson</td>
<td>Professor of Surgery, University of Melbourne; Co-Chair, Melanoma and Skin Service, Peter MacCallum Cancer Centre, VIC</td>
<td>VIC</td>
</tr>
<tr>
<td>Lead Author</td>
<td>A/Professor Angela Hong</td>
<td>Radiation Oncologist, Melanoma Institute Australia; Clinical Associate Professor, Medicine, The University of Sydney</td>
<td>NSW</td>
</tr>
<tr>
<td>Lead Author</td>
<td>Dr Julie Howle</td>
<td>Clinical Senior Lecturer, Surgery, The University of Sydney</td>
<td>NSW</td>
</tr>
<tr>
<td>Lead Author</td>
<td>A/Professor T Michael Hughes</td>
<td>Associate Professor, Surgery, The University of Sydney; Surgeon, Sydney Adventist Hospital</td>
<td>NSW</td>
</tr>
<tr>
<td>Lead Author</td>
<td>Professor Richard Kefford AM</td>
<td>Professor of Cancer Medicine, Macquarie University</td>
<td>NSW</td>
</tr>
<tr>
<td>Management Committee member</td>
<td>Professor John Kelly</td>
<td>Dermatologist and Head, Victorian Melanoma Service, Alfred Hospital</td>
<td>NSW</td>
</tr>
<tr>
<td>Management Committee member</td>
<td>Professor Georgina Long</td>
<td>Executive Director, Melanoma Institute Australia (until December 2016); Senior Surgeon, Melanoma Institute Australia; Professor of Melanoma and Surgical Oncology, The University of Sydney</td>
<td>NSW</td>
</tr>
<tr>
<td>Lead Author</td>
<td>Professor Graham Mann</td>
<td>Chair, University of Sydney Cancer Research Network and Cancer SPARC Steering Committee; Co-Director, Centre for Cancer Research, Westmead Millennium Institute; Research Director, Melanoma Institute Australia, NSW</td>
<td>NSW</td>
</tr>
<tr>
<td></td>
<td>Dr Victoria</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Role</td>
<td>Member name</td>
<td>Specialty/position</td>
<td>State</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>-------------------</td>
<td>------------------------------------------------------------------------------------</td>
<td>-------</td>
</tr>
<tr>
<td>Lead Author</td>
<td>Mar</td>
<td>Dermatologist, Armadale Dermatology, NSW</td>
<td>NSW</td>
</tr>
<tr>
<td>Lead Author</td>
<td>Professor Scott Menzies</td>
<td>The Sydney Melanoma Diagnostic Centre, Royal Prince Alfred Hospital; Professor, Discipline of Dermatology, The University of Sydney</td>
<td>NSW</td>
</tr>
<tr>
<td>Lead Author</td>
<td>Professor Michael Millward</td>
<td>Professor of Clinical Cancer Research, The University of Western Australia; Consultant Medical Oncologist, Sir Charles Gardiner Hospital</td>
<td>WA</td>
</tr>
<tr>
<td>Lead Author</td>
<td>Dr Rachael Morton</td>
<td>Director of Health Economics, NHMRC Clinical Trials Centre, The University of Sydney</td>
<td>NSW</td>
</tr>
<tr>
<td>Management Committee member</td>
<td>A/Professor Susan Neuhaus</td>
<td>General Surgeon and Surgical Oncologist, Royal Adelaide Hospital; Clinical Associate Professor, University of Adelaide Department of Surgery; Associate Professor, Conflict Medicine, University of Adelaide</td>
<td>SA</td>
</tr>
<tr>
<td>Management Committee member</td>
<td>Dr Annette Pflugfelder</td>
<td>Research Higher Degree Student, The School of Medicine, The University of Queensland</td>
<td>QLD</td>
</tr>
<tr>
<td>Lead Author</td>
<td>Dr Robyn Saw</td>
<td>Senior Lecturer, Surgery, The University of Sydney; Surgical Oncologist; General Surgeon, Melanoma Institute Australia and Royal Prince Alfred &amp; Mater Hospitals</td>
<td>NSW</td>
</tr>
<tr>
<td>Management Committee member</td>
<td>Professor Richard Scolyer</td>
<td>Co-Medical Director, Melanoma Institute Australia (from December 2016); Clinical Professor, Pathology, The University of Sydney, NSW</td>
<td>NSW</td>
</tr>
<tr>
<td>Lead Author</td>
<td>A/Professor Michael Sladden</td>
<td>Dermatologist, Tas Derm</td>
<td>TAS</td>
</tr>
<tr>
<td>Lead Author</td>
<td>Professor H Peter Soyer</td>
<td>Director, School of Medicine, University of Queensland</td>
<td>QLD</td>
</tr>
<tr>
<td>Lead Author</td>
<td>A/Professor Andrew Spillane</td>
<td>Associate Professor, Surgical Oncology, The University of Sydney</td>
<td>NSW</td>
</tr>
<tr>
<td>Management Committee member</td>
<td>Professor</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Clinical practice guidelines for the diagnosis and management of melanoma

### 8.2.4 Cancer Council Australia Project Team

<table>
<thead>
<tr>
<th>Role</th>
<th>Member name</th>
<th>Specialty/position</th>
<th>State</th>
</tr>
</thead>
<tbody>
<tr>
<td>CCA Project Team member</td>
<td>Laura Wuellner</td>
<td>Project Manager, Clinical Guidelines Network (until November 2016); Acting Head, Clinical Guidelines Network (from November 2016)</td>
<td>NSW</td>
</tr>
<tr>
<td>CCA Project Team member</td>
<td>Katrina Anderson</td>
<td>Project Manager, Clinical Guidelines Network (from November 2016)</td>
<td>NSW</td>
</tr>
<tr>
<td>CCA Systematic Literature Reviewer Team member</td>
<td>Lani Teddy</td>
<td>Project Officer, Systematic Literature Reviews, Melanoma Guidelines (until December 2016)</td>
<td>NSW</td>
</tr>
</tbody>
</table>
### 8.2.5 Sub-committee membership for each guideline question

For each guideline question, the guideline question lead author under consultation with the Management Committee established a sub-committee with relevant expert members of the working party and co-opted additional external clinical experts as required.

The role of the sub-committee is to review the draft content for the guideline questions of the section before it is presented to the working party.

#### WHAT ARE THE CLINICAL FEATURES OF MELANOMA AND HOW DO ATYPICAL MELANOMAS PRESENT?

*Question lead: Victoria Mar*

<table>
<thead>
<tr>
<th>Sub-committee members</th>
</tr>
</thead>
<tbody>
<tr>
<td>Name</td>
</tr>
<tr>
<td>Dr Alex Chamberlain</td>
</tr>
<tr>
<td>Professor Stephen Lee AM</td>
</tr>
<tr>
<td>Dr Bill Murray</td>
</tr>
<tr>
<td>Professor John Kelly</td>
</tr>
</tbody>
</table>

### WHAT TYPE OF BIOPSY SHOULD BE PERFORMED FOR A SUSPICIOUS PIGMENTED
**SKIN LESION?**

*Question lead: Professor John Kelly*

<table>
<thead>
<tr>
<th>Name</th>
<th>Position/speciality</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr Trevor Beer</td>
<td>Histopathologist, Clinipath Pathology, WA</td>
</tr>
<tr>
<td>Professor Diona Damian</td>
<td>Professor of Dermatology, The University of Sydney, NSW</td>
</tr>
<tr>
<td>Jonathan Ng</td>
<td>Honorary Research Fellow, Victorian Melanoma Service, The Alfred Hospital, VIC</td>
</tr>
<tr>
<td>Dr Joseph Ohana</td>
<td>GP, The Village Medical Practice, NSW</td>
</tr>
<tr>
<td>Professor Richard Scolyer</td>
<td>Co-Medical Director, Melanoma Institute Australia (from December 2016); Clinical Professor, Pathology, The University of Sydney, NSW</td>
</tr>
<tr>
<td>Professor H Peter Soyer</td>
<td>Director, School of Medicine, University of Queensland, QLD</td>
</tr>
</tbody>
</table>

**WHEN IS A SENTINEL NODE BIOPSY INDICATED?**

*Question lead: Dr David Gyorki*

<table>
<thead>
<tr>
<th>Name</th>
<th>Position/speciality</th>
</tr>
</thead>
<tbody>
<tr>
<td>A/Professor Andrew Barbour</td>
<td>General Surgeon, Greenslopes Private Hospital, Princess Alexandra Hospital, QLD</td>
</tr>
<tr>
<td>Dr Victoria Marc</td>
<td>Dermatologist</td>
</tr>
<tr>
<td>Dr Mark Hanikeri</td>
<td>Director, Western Australia Plastic Surgery Centre, WA</td>
</tr>
<tr>
<td>Dr Shahneen Sandhu</td>
<td>Medical Oncologist, Peter MacCallum Cancer Centre, VIC</td>
</tr>
</tbody>
</table>

**WHAT ARE THE RECOMMENDED DEFINITIVE MARGINS FOR EXCISION OF PRIMARY MELANOMA?**

*Question lead: A/Professor Michael Sladden*

<table>
<thead>
<tr>
<th>Name</th>
<th>Position/speciality</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr Julie Howle</td>
<td>Clinical Senior Lecturer, Surgery, The University of Sydney, NSW</td>
</tr>
</tbody>
</table>
WHAT IS THE ROLE OF DERMOSCOPY (AND SEQUENTIAL DERMOSCOPY) IN MELANOMA DIAGNOSIS?

**Question lead: Professor Scott Menzies**

<table>
<thead>
<tr>
<th>Sub-committee members</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Name</td>
<td>Position/speciality</td>
</tr>
<tr>
<td>Dr Alex Chamberlain</td>
<td>Dermatologist, The Alfred Hospital, VIC</td>
</tr>
<tr>
<td>A/Professor Pascale Guitera</td>
<td>Senior Research Fellow, Dermatology, The University of Sydney, NSW</td>
</tr>
<tr>
<td>Professor H Peter Soyer</td>
<td>Director, School of Medicine, University of Queensland, QLD</td>
</tr>
</tbody>
</table>

WHAT IS THE APPROPRIATE TREATMENT FOR MACROSCOPIC (I.E. DETECTABLE CLINICALLY OR BY ULTRASOUND) NODAL METASTASIS?

**Question lead: Professor Michael Henderson**

<table>
<thead>
<tr>
<th>Sub-committee members</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Name</td>
<td>Position/speciality</td>
</tr>
<tr>
<td>A/Professor T Michael Hughes</td>
<td>Associate Professor, Surgery, The University of Sydney; Surgeon, Sydney Adventist Hospital, NSW</td>
</tr>
<tr>
<td>A/Professor Mark Smithers</td>
<td>Associate Professor, Department of Surgery, The University of Queensland, QLD</td>
</tr>
<tr>
<td>A/Professor Andrew Spillane</td>
<td>Associate Professor, Surgical Oncology, The University of Sydney</td>
</tr>
<tr>
<td>Dr John Spillane</td>
<td>General Surgeon, Epworth Eastern Consulting, VIC</td>
</tr>
</tbody>
</table>

SHOULD ALL PATIENTS WITH A POSITIVE SENTINEL LYMPH NODE BIOPSY HAVE A COMPLETE NODE DISSECTION?

**Question lead: A/Professor Andrew Spillane**

<table>
<thead>
<tr>
<th>Sub-committee members</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Name</td>
<td>Position/speciality</td>
</tr>
</tbody>
</table>
### WHAT INVESTIGATIONS SHOULD BE PERFORMED FOLLOWING A DIAGNOSIS OF PRIMARY CUTANEOUS MELANOMA FOR ASYMPTOMATIC STAGE I AND II PATIENTS?

**Question lead: Dr Rachael Morton**

<table>
<thead>
<tr>
<th>Name</th>
<th>Position/speciality</th>
</tr>
</thead>
<tbody>
<tr>
<td>A/Professor Andrew Barbour</td>
<td>General Surgeon, Greenslopes Private Hospital, Princess Alexandra Hospital, QLD</td>
</tr>
<tr>
<td>Dr Victoria Mar</td>
<td>Dermatologist, Armadale Dermatology, NSW</td>
</tr>
<tr>
<td>A/Professor Mark Smithers</td>
<td>Associate Professor, Department of Surgery, The University of Queensland, QLD</td>
</tr>
<tr>
<td>A/Professor Jonathan Stretch AM</td>
<td>Associate Professor of Melanoma and Skin Oncology, The University of Sydney, NSW</td>
</tr>
</tbody>
</table>

### WHAT INVESTIGATIONS SHOULD BE PERFORMED WHEN IN TRANSIT AND/OR REGIONAL NODE DISEASE (STAGE III MELANOMA) IS DIAGNOSED?

**Question lead: Dr Robyn Saw**

<table>
<thead>
<tr>
<th>Name</th>
<th>Position/speciality</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr Andrew Haydon</td>
<td>Medical Oncologist, Alfred Hospital and Cabrini Health, VIC</td>
</tr>
<tr>
<td>Professor Grant McArthur</td>
<td>Head, Molecular Oncology Laboratory and Translational Research Laboratory, Co-Chair, Melanoma and Skin Service, Peter MacCallum Cancer Centre, VIC</td>
</tr>
<tr>
<td>Dr Alex Menzies</td>
<td>Medical Oncologist, Royal North Shore Hospital, NSW</td>
</tr>
<tr>
<td>Dr John</td>
<td></td>
</tr>
</tbody>
</table>
## WHAT INVESTIGATIONS SHOULD BE PERFORMED WHEN STAGE IV MELANOMA IS DIAGNOSED?

**Question lead:** Professor Michael Millward

<table>
<thead>
<tr>
<th>Name</th>
<th>Position/speciality</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr Victoria Atkinson</td>
<td>Senior Staff Specialist, Princess Alexandra Hospital; Visiting Medical Oncologist, Greenslopes Private Hospital, QLD</td>
</tr>
<tr>
<td>Dr Michael Brown</td>
<td>Medical Oncologist, Royal Adelaide Hospital, SA</td>
</tr>
<tr>
<td>Dr Andrew Haydon</td>
<td>Medical Oncologist, Alfred Hospital and Cabrini Health, VIC</td>
</tr>
<tr>
<td>Dr Alex Menzies</td>
<td>Medical Oncologist, Royal North Shore Hospital, NSW</td>
</tr>
</tbody>
</table>

## HOW SHOULD PATIENTS AT EACH STAGE OF MELANOMA BE FOLLOWED AFTER INITIAL DEFINITIVE TREATMENT?

**Question lead:** A/Professor Andrew Barbour

<table>
<thead>
<tr>
<th>Name</th>
<th>Position/speciality</th>
</tr>
</thead>
<tbody>
<tr>
<td>A/Professor Alexander Guminski</td>
<td>Associate Professor, Medicine, The University of Sydney, Medical Oncologist, Melanoma Institute Australia, North Shore Private Hospital, and Royal North Shore Hospital, NSW</td>
</tr>
<tr>
<td>Wendy Liu</td>
<td>Dermatologist, Alfred Hospital, Peter MacCallum Cancer Centre, Victorian Melanoma Service, VIC</td>
</tr>
<tr>
<td>Professor Scott Menzies</td>
<td>The Sydney Melanoma Diagnostic Centre, Royal Prince Alfred Hospital; Professor, Discipline of Dermatology, The University of Sydney, NSW</td>
</tr>
<tr>
<td>Dr Rachael Morton</td>
<td>Senior Research Fellow, Public Health, The University of Sydney, NSW</td>
</tr>
</tbody>
</table>
WHO IS AT HIGH RISK OF MELANOMA?

*Question lead: Professor Graham Mann*

### Sub-committee members

<table>
<thead>
<tr>
<th>Name</th>
<th>Position/speciality</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr Anne Cust</td>
<td>Senior Research Fellow, Public Health, The University of Sydney, NSW</td>
</tr>
<tr>
<td>Professor Diona Damian</td>
<td>Professor of Dermatology, The University of Sydney, NSW</td>
</tr>
<tr>
<td>Professor H Peter Soyer</td>
<td>Director, School of Medicine, University of Queensland, QLD</td>
</tr>
<tr>
<td>Professor David Whiteman</td>
<td>Senior Principal Research Fellow and Head, Cancer Control, Queensland Institute of Medical Research Berghofer Medical Research Institute, QLD</td>
</tr>
<tr>
<td>Dr Paul Fishburn</td>
<td>GP, The Village Medical Practice, NSW</td>
</tr>
<tr>
<td>Professor John Kelly</td>
<td>Dermatologist and Head, Victorian Melanoma Service, Alfred Hospital</td>
</tr>
<tr>
<td>Dr Rachael Morton</td>
<td>Senior Research Fellow, Public Health, The University of Sydney, NSW</td>
</tr>
<tr>
<td>Dr Victoria Mar</td>
<td>Dermatologist, Armadale Dermatology, NSW</td>
</tr>
</tbody>
</table>

WHAT CLINICAL INFORMATION SHOULD THE PATHOLOGIST GIVE THE CLINICIAN TO AID DIAGNOSIS OF MELANOMA?

*Question lead: Dr Craig James*

### Sub-committee members

<table>
<thead>
<tr>
<th>Name</th>
<th>Position/speciality</th>
</tr>
</thead>
<tbody>
<tr>
<td>A/Professor Brendon Coventry</td>
<td>Associate Professor, Department of Surgery, The University of Adelaide; Senior Consultant Surgeon, Royal Adelaide Hospital, SA</td>
</tr>
<tr>
<td>Professor Richard Scolyer</td>
<td>Co-Medical Director, Melanoma Institute Australia (from December 2016); Clinical Professor, Pathology, The University of Sydney, NSW</td>
</tr>
<tr>
<td>Professor Stephen Lee AM</td>
<td>Professor of Dermatology, The University of Sydney, NSW</td>
</tr>
<tr>
<td>Professor Catriona McLean</td>
<td>Director, Pathology Board, Monash University; Director, Anatomical Pathology, The Alfred Hospital, VIC</td>
</tr>
</tbody>
</table>
**WHAT IS THE ROLE OF ADJUVANT SYSTEMIC THERAPY IN PATIENTS WITH RESECTED STAGE 3 MELANOMA?**

*Question lead: Dr Matteo Carlino*

<table>
<thead>
<tr>
<th>Sub-committee members</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
</tr>
<tr>
<td>Professor Catriona McLean</td>
</tr>
<tr>
<td>Professor Richard Kefford AM</td>
</tr>
</tbody>
</table>

**IS ADJUVANT RADIOTHERAPY OF VALUE FOLLOWING RESECTION OF INVOLVED LYMPH NODES?**

*Question lead: Professor Graham Stevens*

<table>
<thead>
<tr>
<th>Sub-committee members</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
</tr>
<tr>
<td>Professor Bryan Burmeister</td>
</tr>
<tr>
<td>Dr Gerald Fogarty</td>
</tr>
<tr>
<td>Professor Michael Henderson</td>
</tr>
</tbody>
</table>

**FOR PATIENTS WITH DISTANT METASTASES, WHEN IS SURGICAL THERAPY INDICATED?**

*Question lead: A/Prof Andrew Spillane*

<table>
<thead>
<tr>
<th>Sub-committee members</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
</tr>
<tr>
<td>A/Professor Andrew Barbour</td>
</tr>
</tbody>
</table>
Clinical practice guidelines for the diagnosis and management of melanoma

Dr Julie Howle  Clinical Senior Lecturer, Surgery, The University of Sydney, NSW

Back to top

**WHAT RADIOTHERAPY IS INDICATED FOR PATIENTS WITH DISTANT METASTASES?**

*Question lead: A/Professor Angela Hong*

<table>
<thead>
<tr>
<th>Name</th>
<th>Position/speciality</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr Gerald Fogarty</td>
<td>Director, Radiation Oncology, Mater Hospital, NSW</td>
</tr>
<tr>
<td>Professor Graham Stevens</td>
<td>Director of Radiation Oncology, Orange General Hospital, NSW</td>
</tr>
</tbody>
</table>

Back to top

**DOES SYSTEMIC DRUG THERAPY IMPROVE PROGRESSION FREE AND/OR OVERALL SURVIVAL IN STAGE 3C UNRESECTABLE AND STAGE 4 MELANOMA?**

*Question lead: Professor Georgina Long*

<table>
<thead>
<tr>
<th>Name</th>
<th>Position/speciality</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr Matteo Carlino</td>
<td>Medical Oncologist, The Crown Princess Mary Cancer Centre, Westmead, NSW</td>
</tr>
<tr>
<td>Professor Richard Kefford AM</td>
<td>Professor of Cancer Medicine, Macquarie University, NSW</td>
</tr>
<tr>
<td>Professor Grant McArthur</td>
<td>Head, Molecular Oncology Laboratory and Translational Research Laboratory, Co-Chair, Melanoma and Skin Service, Peter MacCallum Cancer Centre, VIC</td>
</tr>
<tr>
<td>Dr Alex Menzies</td>
<td>Medical Oncologist, Royal North Shore Hospital, NSW</td>
</tr>
<tr>
<td>Dr Mark Shackleton</td>
<td>Group Leader, Cancer Development and Treatment Laboratory, Peter MacCallum Cancer Centre, NSW</td>
</tr>
</tbody>
</table>

Back to top

**HOW SHOULD LENTIGO MALIGNA BE MANAGED?**

*Question lead: Professor H Peter Soyer*

<table>
<thead>
<tr>
<th>Name</th>
<th>Position/speciality</th>
</tr>
</thead>
</table>

These guidelines have been developed as web-based guidelines and the pdf serves as a reference copy only. Please note that this material was published on 16:43, 6 April 2017 and is no longer current.
SHOULD DESMOPLASTIC AND/OR NEUROTROPIC MELANOMAS BE TREATED DIFFERENTLY?

*Question lead: A/Professor T Michael Hughes*

**Sub-committee members**

<table>
<thead>
<tr>
<th>Name</th>
<th>Position/speciality</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Foote</td>
<td>TBC</td>
</tr>
<tr>
<td>Professor John Kelly</td>
<td>Dermatologist and Head, Victorian Melanoma Service, Alfred Hospital</td>
</tr>
<tr>
<td>Professor Richard Scolyer</td>
<td>Co-Medical Director, Melanoma Institute Australia (from December 2016); Clinical Professor, Pathology, The University of Sydney, NSW</td>
</tr>
<tr>
<td>A/Professor Jonathan Stretch AM</td>
<td>Associate Professor of Melanoma and Skin Oncology, The University of Sydney, NSW</td>
</tr>
</tbody>
</table>

HOW SHOULD MELANOMA IN CHILDHOOD BE MANAGED?

*Question lead: Dr Robyn Saw*

**Sub-committee members**

<table>
<thead>
<tr>
<th>Name</th>
<th>Position/speciality</th>
</tr>
</thead>
<tbody>
<tr>
<td>A/Professor Andrew Barbour</td>
<td>General Surgeon, Greenslopes Private Hospital, Princess Alexandra Hospital, QLD</td>
</tr>
<tr>
<td>Dr Mark Hanikeri</td>
<td>Director, Western Australia Plastic Surgery Centre, WA</td>
</tr>
<tr>
<td>Dr Chris McCormack</td>
<td>Consultant Dermatologist, St Vincents Hospital Melbourne, VIC</td>
</tr>
<tr>
<td>Professor Richard</td>
<td>Co-Medical Director, Melanoma Institute Australia (from December 2016); Clinical Professor, Pathology, The University of Sydney, NSW</td>
</tr>
</tbody>
</table>

These guidelines have been developed as web-based guidelines and the pdf serves as a reference copy only. Please note that this material was published on 16:43, 6 April 2017 and is no longer current.
### HOW SHOULD MELANOMA IN PREGNANCY BE MANAGED?

**Question lead:** Dr Julie Howle

**Sub-committee members**

<table>
<thead>
<tr>
<th>Name</th>
<th>Position/speciality</th>
</tr>
</thead>
<tbody>
<tr>
<td>A/Professor Kiarash Khosrotehrani</td>
<td>Clinical Scientist, Centre for Clinical Research, The University of Queensland, QLD</td>
</tr>
<tr>
<td>Dr Robyn Saw</td>
<td>Senior Lecturer, Surgery, The University of Sydney; Surgical Oncologist; General Surgeon, Melanoma Institute Australia and Royal Prince Alfred &amp; Mater Hospitals, NSW</td>
</tr>
</tbody>
</table>

### HOW SHOULD SATELLITE AND IN TRANSIT METASTATIC DISEASE BE MANAGED?

**Question lead:** Professor Michael Henderson

**Sub-committee members**

<table>
<thead>
<tr>
<th>Name</th>
<th>Position/speciality</th>
</tr>
</thead>
<tbody>
<tr>
<td>Professor Diona Damian</td>
<td>Professor of Dermatology, The University of Sydney, NSW</td>
</tr>
<tr>
<td>Professor Omgo Nieweg</td>
<td>Surgeon, Melanoma Institute Australia, NSW</td>
</tr>
<tr>
<td>Dr Robyn Saw</td>
<td>Senior Lecturer, Surgery, The University of Sydney; Surgical Oncologist; General Surgeon, Melanoma Institute Australia and Royal Prince Alfred &amp; Mater Hospitals, NSW</td>
</tr>
<tr>
<td>A/Professor Mark Smithers</td>
<td>Associate Professor, Department of Surgery, The University of Queensland, QLD</td>
</tr>
<tr>
<td>Dr John Spillane</td>
<td>General Surgeon, Epworth Eastern Consulting, VIC</td>
</tr>
</tbody>
</table>
8.2.6 Acknowledgement

Sincere thanks to Professor Ian Olver AM who initiated the Melanoma Guidelines Revision Project in collaboration with Melanoma Institute Australia in 2014 in his role as Chief Executive Officer, Cancer Council Australia. Since February 2015, he has been Director, Sansom Institute for Health Research.

Back to top

8.3 List of clinical questions

Contents

1 Finalised content
2 Public consultation content
3 Content under development (not yet open for public consultation)
4 Systematic reviews underway/pending (not yet open for public consultation)

8.3.1 Finalised content

- What are the clinical features of melanoma and how do atypical melanomas present?
- What type of biopsy should be performed for a suspicious pigmented skin lesion?
- When is a sentinel node biopsy indicated?
- What are the recommended safety margins for radical excision of primary melanoma?

8.3.2 Public consultation content

Diagnostic aids for melanoma

- What is the role of dermoscopy in melanoma diagnosis?
- What is the role of sequential digital dermoscopy imaging in melanoma diagnosis?
- What is the role of automated instruments in melanoma diagnosis?
- What is the role of confocal microscopy in melanoma diagnosis?

What is the appropriate treatment for macroscopic (i.e. detectable clinically or by ultrasound) nodal metastasis?
8.3.3 Content under development (not yet open for public consultation)

- Should all patients with a positive sentinel lymph node biopsy have a complete node dissection?
- What investigations should be performed following a diagnosis of primary cutaneous melanoma for asymptomatic Stage I and II patients?
- What investigations should be performed when in transit and/or regional node disease (Stage III melanoma) is diagnosed?
- What investigations should be performed when Stage IV melanoma is diagnosed?
- How should patients at each stage of melanoma be followed after initial definitive treatment?
- What is the ideal setting, duration and frequency of follow-up for melanoma patients?

8.3.4 Systematic reviews underway/pending (not yet open for public consultation)

- Who is at risk of melanoma?
- What is the evidence for the use of skin surface imaging in the early diagnosis of patients at high risk of developing melanoma? (Total body photography) (Question wording to be confirmed.)
- What clinical information should the pathologist give the clinician to aid diagnosis of melanoma?
- What is the role of adjuvant systemic therapy in patients with resected stage 3 melanoma?
- Is adjuvant radiotherapy of value following resection of involved lymph nodes?
- Does systemic drug therapy improve progression free and/or overall survival in stage 3c unresectable and stage 4 melanoma?
- For patients with distant metastases, when is surgical therapy indicated?
- What radiotherapy is indicated for patients with distant metastasis?
- Should desmoplastic and/or neurotropic melanomas be treated differently?
- How should lentigo maligna be managed?
- How should satellite and in transit metastatic disease be managed?
- How should melanoma in pregnancy be managed?
- How should melanoma in children be managed?
8.4 Declarations of interest register

Conflict of interest register